Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2015	Feb. 23, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Trading Symbol	iart
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Central Index Key	0000917520
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,741
Entity Common Stock, Shares Outstanding		37,000,721

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Total revenue, net	$ 882,734	$ 796,717	$ 696,832
Costs and Expenses:
Cost of goods sold	326,542	302,946	279,548
Research and development	50,895	43,559	42,622
Selling, general and administrative	415,757	375,545	332,190
Intangible asset amortization	9,953	6,810	7,099
Total costs and expenses	803,147	728,860	661,459
Operating income	79,587	67,857	35,373
Interest income	13	168	4,933
Interest expense	(23,517)	(21,967)	(19,725)
Other income (expense), net	4,588	(492)	(1,795)
Income from continuing operations before income taxes	60,671	45,566	18,786
Provision (benefit) for income taxes	53,820	9,271	(3,241)
Net income from continuing operations	6,851	36,295	22,027
Loss from discontinued operations (net of tax benefit)	(10,370)	(2,291)	(43,094)
Net (loss) income	$ (3,519)	$ 34,004	$ (21,067)
Income from continuing operations	$ 0.20	$ 1.12	$ 0.78
Loss from discontinued operations	(0.30)	(0.07)	(1.52)
Net (loss) income per share - basic	(0.10)	1.05	(0.74)
Income from continuing operations	0.19	1.10	0.76
Loss from discontinued operations	(0.29)	(0.07)	(1.50)
Net (loss) income per share - diluted	$ (0.10)	$ 1.03	$ (0.74)
Weighted average common shares outstanding (See Note 12):
Basic (in shares)	34,495	32,432	28,416
Diluted (in shares)	35,677	32,960	28,802

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (3,519)	$ 34,004	$ (21,067)
Other comprehensive income (loss), before tax:
Change in foreign currency translation adjustments	(25,841)	(26,674)	5,874
Unrealized loss on derivatives
Unrealized derivative losses arising during period	(25)	(206)	(110)
Less: Reclassification adjustments for losses included in net income (loss)	(923)	(1,747)	(1,830)
Unrealized gain on derivatives	898	1,541	1,720
Defined benefit pension plan
Defined benefit pension plan - net gain (loss) arising during period	904	1,672	(1,398)
Total other comprehensive income (loss), before tax	(24,039)	(23,461)	6,196
Income tax (expense) benefit related to items in other comprehensive income (loss)	(375)	(954)	(472)
Total other comprehensive income (loss), net of tax	(24,414)	(24,415)	5,724
Comprehensive income (loss), net of tax	$ (27,933)	$ 9,589	$ (15,343)

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 48,132	$ 71,734
Restricted cash and cash equivalents	4,073	0
Trade accounts receivable, net of allowances of $5,572 and $5,659	132,241	110,414
Inventories, net	211,429	189,133
Deferred tax assets	0	30,564
Prepaid expenses and other current assets	42,620	27,691
Current assets of discontinued operations	0	99,785
Total current assets	438,495	529,321
Property, plant and equipment, net	205,181	193,626
Intangible assets, net	603,740	412,568
Goodwill	512,389	363,479
Deferred tax assets	6,932	4,471
Other assets	7,967	10,220
Non-current assets of discontinued operations	0	73,734
Total assets	1,774,704	1,587,419
Current Liabilities:
Borrowings under senior credit facility	14,375	3,750
Accounts payable, trade	34,772	28,867
Deferred revenue	5,666	5,176
Accrued compensation	45,154	34,643
Accrued expenses and other current liabilities	39,160	39,809
Current liabilities of discontinued operations	0	13,780
Total current liabilities	139,127	126,025
Long-term borrowings under senior credit facility	481,875	413,125
Long-term convertible securities	218,720	213,121
Deferred tax liabilities	154,891	100,417
Other liabilities	28,648	27,778
Long-term liabilities of discontinued operations	0	2,631
Total liabilities	$ 1,023,261	$ 883,097
Commitments and contingencies
Stockholders’ Equity:
Preferred Stock; no par value; 15,000 authorized shares; none outstanding	$ 0	$ 0
Common stock; $0.01 par value; 60,000 authorized shares; 45,857 and 41,644 issued at December 31, 2015 and 2014, respectively	459	416
Additional paid-in capital	1,020,128	779,555
Treasury stock, at cost; 8,915 and 8,907 shares at December 31, 2015 and 2014, respectively	(367,121)	(367,121)
Accumulated other comprehensive loss	(47,902)	(23,488)
Retained earnings	145,879	314,960
Total stockholders’ equity	751,443	704,322
Total liabilities and stockholders’ equity	$ 1,774,704	$ 1,587,419

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Trade accounts receivable, allowances	$ 5,572	$ 5,659
Preferred Stock, par value (in dollars per share)
Preferred Stock, authorized shares (in shares)	15,000,000	15,000,000
Preferred Stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	45,857,000	41,644,000
Treasury stock, shares (in shares)	8,915,000	8,907,000

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Cash Flows [Abstract]
Net (loss) income	$ (3,519)	$ 34,004	$ (21,067)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Loss from discontinued operations, net of tax	10,370	2,291	43,094
Depreciation and amortization	58,863	46,434	31,013
Non-cash impairment charges	380	790	340
Deferred income tax provision (benefit)	(351)	(6,849)	(1,341)
Non-cash valuation allowance	37,210	0	0
Share-based compensation	15,450	14,554	9,842
Amortization of debt issuance costs	2,264	2,571	2,298
Non-cash interest expense	7,911	7,104	6,463
Payment of accreted interest	(384)	0	0
Loss on disposal of property and equipment	481	909	1,965
Excess tax benefits from stock-based compensation arrangements	(3,792)	(1,384)	(270)
Change in fair value of contingent consideration	(177)	(764)	0
Gain on bargain purchase	(1,111)	0	0
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	(16,231)	(17,145)	1,010
Inventories	(3,759)	(24,138)	(27,364)
Prepaid expenses and other current assets	(233)	16,526	1,996
Other non-current assets	610	(10,914)	1,872
Accounts payable, accrued expenses and other current liabilities	1,629	(1,907)	1,334
Deferred revenue	136	1,118	697
Other non-current liabilities	945	(4,357)	1,159
Net cash provided by operating activities of continuing operations	106,692	58,843	53,041
Net cash (used in) provided by operating activities of discontinued operations	(12,209)	20,620	227
Net cash provided by operating activities	94,483	79,463	53,268
INVESTING ACTIVITIES:
Change in restricted cash	(4,087)	0	0
Cash used in business acquisitions, net of cash acquired	(328,888)	(320,921)	(2,980)
Purchases of property and equipment	(33,413)	(38,340)	(42,301)
Sales of property and equipment	1,438	0	535
Other changes in intangible assets	0	(475)	0
Net cash used in investing activities of continuing operations	(364,950)	(359,736)	(44,746)
Net cash used in investing activities of discontinued operations	(7,060)	(3,581)	(5,550)
Net cash used in investing activities	(372,010)	(363,317)	(50,296)
FINANCING ACTIVITIES:
Borrowings under senior credit facility	545,000	425,000	30,000
Repayments under senior credit facility	(465,625)	(195,000)	(165,000)
Proceeds from the issuance of common stock, net of issuance costs	219,669	0	152,458
Distribution to SeaSpine	(47,013)	0	0
Payment of liability component of convertible notes	(2,519)	0	0
Payment of capital lease obligation	(709)	(605)	0
Debt issuance costs	(1,426)	(3,210)	(1,053)
Proceeds from exercised stock options	7,345	15,215	2,344
Excess tax benefits from stock-based compensation arrangements	3,791	1,384	270
Net cash provided by financing activities	258,513	242,784	19,019
Effect of exchange rate changes on cash and cash equivalents	(4,848)	(7,550)	1,685
Net (decrease) increase in cash and cash equivalents	(23,862)	(48,620)	23,676
Cash and cash equivalents at beginning of period	71,994	120,614	96,938
Cash and cash equivalents at end of period	$ 48,132	$ 71,994	$ 120,614

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	SeaSpine	SeaSpine Accumulated Other Comprehensive Income (Loss)	SeaSpine Retained Earnings
Balance at Dec. 31, 2012	$ 517,775	$ 369	$ (367,121)	$ 587,301	$ (4,797)	$ 302,023
Common Stock, shares at Dec. 31, 2012		36,852,000
Treasury Stock, shares at Dec. 31, 2012			(8,907,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(21,067)					(21,067)
Other comprehensive income (loss), net of tax	5,724				5,724
Issuance of common stock	152,458	$ 40		152,418
Issuance of common stock, shares		4,025,000
Issuance of common stock through employee benefit plans	234	$ 0		234
Issuance of common stock through employee benefit plans, shares		6,000
Share-based compensation	10,966	$ 1		10,965
Share-based compensation, shares		159,000
Treasury Stock, shares at Dec. 31, 2013			(8,907,000)
Common Stock, shares at Dec. 31, 2013		41,042,000
Balance at Dec. 31, 2013	666,090	$ 410	$ (367,121)	750,918	927	280,956
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	34,004					34,004
Other comprehensive income (loss), net of tax	(24,415)				(24,415)
Issuance of common stock through employee benefit plans	286	$ 0		286
Issuance of common stock through employee benefit plans, shares		6,000
Share-based compensation	$ 28,357	$ 6		28,351
Share-based compensation, shares		596,000
Treasury Stock, shares at Dec. 31, 2014	(8,907,000)		(8,907,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Share purchases	0
Common Stock, shares at Dec. 31, 2014		41,644,000
Balance at Dec. 31, 2014	$ 704,322	$ 416	$ (367,121)	779,555	(23,488)	314,960
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(3,519)					(3,519)
Other comprehensive income (loss), net of tax	(24,414)
Issuance of common stock	219,680	$ 40		219,640
Separation of SeaSpine							$ (167,229)	$ (1,667)	$ (165,562)
Other comprehensive income (loss), net of tax	(22,747)				(22,747)
Issuance of common stock, shares		4,003,000
Issuance of common stock through employee benefit plans	231			231
Issuance of common stock through employee benefit plans, shares		4,000
Share-based compensation	$ 20,705	$ 3		20,702
Share-based compensation, shares		206,000
Treasury Stock, shares at Dec. 31, 2015	(8,915,000)		(8,915,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Share purchases	0		(8,000)
Common Stock, shares at Dec. 31, 2015		45,857,000
Balance at Dec. 31, 2015	$ 751,443	$ 459	$ (367,121)	$ 1,020,128	$ (47,902)	$ 145,879

BUSINESS	12 Months Ended
BUSINESS	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS Integra LifeSciences Holdings Corporation (the “Company”) was incorporated in Delaware in 1989. The Company, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Its products are used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. The Company sells its products directly through various sales forces and through a variety of other distribution channels.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

These financial statements and the accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America and conform to Regulation S-X under the Securities Exchange Act of 1934, as amended.

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly owned. All intercompany accounts and transactions are eliminated in consolidation. See Note 4, Acquisitions and Pro Forma Results, for details of new subsidiaries included in the consolidation.

On July 1, 2015, the Company completed the distribution of 100% of the outstanding common shares of SeaSpine Holdings Corporation ("SeaSpine") to Integra shareholders who received one share of SeaSpine common stock for every three shares of Integra common stock held as of the close of business on the record date, June 19, 2015. The Company has classified the results of operations, cash flows, and related assets and liabilities of SeaSpine as discontinued operations for all periods presented in the Company's Form 10-K. Unless indicated otherwise, the information in the Notes to the consolidated financial statements relates to the Company's continuing operations. Refer to Note 3, Discontinued Operations, for additional information regarding the distribution.

USE OF ESTIMATES

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets and in-process research and development ("IPR&D"), amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows, depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of pension assets and liabilities, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, and valuation of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.

OUT OF PERIOD ADJUSTMENTS

In the fourth quarter of 2013, income tax benefit was increased by $1.0 million for the cumulative effect of immaterial errors related to the Company's reserve for uncertain tax positions that related to prior periods. Of the $1.0 million increase, $0.9 million was to correct an error that was recorded in the deferred tax accounts in 2011, and the remainder of the error had an insignificant impact across 2012 and 2013. Based upon the Company's evaluation of relevant factors related to this matter, it concluded that the uncorrected adjustments in the previously issued consolidated financial statements for any of the periods affected are immaterial and that the impact of recording the cumulative correction in the fourth quarter of 2013 is not material to its earnings for the full year ending December 31, 2013.

RECLASSIFICATIONS

Certain amounts from the prior years' financial statements have been reclassified in order to conform to the current year's presentation.

CASH AND CASH EQUIVALENTS

The Company considers all short-term, highly liquid investments purchased with original maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.

RESTRICTED CASH AND CASH EQUIVALENTS

Restricted cash and cash equivalents represents cash that is not available for use in our operations. The Company had restricted cash and cash equivalents of $4.1 million as of December 31, 2015. There was no restricted cash as of December 31, 2014.

TRADE ACCOUNTS RECEIVABLE AND ALLOWANCES FOR DOUBTFUL ACCOUNTS RECEIVABLE

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.

The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowances for doubtful accounts is recorded based on factors including the length of time the receivables are past due, the current business environment and the Company's historical experience. Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered.

INVENTORIES

Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or market. Inventories consisted of the following:



	December 31,
	2015		2014
	(In thousands)
Finished goods	$	125,869	$	120,477
Work in process	47,962		38,938
Raw materials	37,598		29,718
Total inventories, net	$	211,429	$	189,133

At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.

The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management's judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program. No such amounts were capitalized at December 31, 2015 or 2014.

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software developed or obtained for internal use is accounted for in accordance with the Accounting Standards Codification 350-40, Internal-Use Software.

Property, plant and equipment balances and corresponding lives were as follows:



	December 31,
	2015			2014			Useful Lives
	(In thousands)
Land	$	2,189		$	3,308
Buildings and building improvements	17,611			16,271			5-40 years
Leasehold improvements	75,575			41,154			1-20 years
Machinery and production equipment	103,083			86,010			3-20 years
Surgical instrument kits	15,916			10,758			4-5 years
Information systems and hardware	93,742			90,672			1-7 years
Furniture, fixtures, and office equipment	15,010			14,861			1-15 years
Construction-in-progress	50,571			78,055
Total	373,697			341,089
Less: Accumulated depreciation	(168,516		)	(147,463		)
Property, plant and equipment, net	$	205,181		$	193,626

Depreciation expense associated with property, plant and equipment was $27.0 million, $23.7 million, and $19.9 million for the years ended December 31, 2015, 2014 and 2013, respectively.

The Company leases certain computer equipment under capital lease agreements. The gross carrying value of such leases amounted to $2.0 million at December 31, 2015 and 2014. The accumulated depreciation of such leases amounted to $1.3 million and $0.7 million at December 31, 2015 and 2014, respectively, and the cost is included as a component of furniture, fixtures, office equipment and information systems and hardware.

CAPITALIZED INTEREST

The interest cost on capital projects, including facilities build-out and internal use software, is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. For the years ended December 31, 2015 and 2014, respectively, the Company capitalized $1.7 million and $2.6 million and of interest expense into property, plant and equipment.

ACQUISITIONS

Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. The fair value of development, regulatory, and commercial milestone payments reflects management’s expectations of probability of payment, and increases or decreases as the probability of payment or expectation of timing of payments changes. The fair value of sales-based payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.

GOODWILL AND OTHER INTANGIBLE ASSETS

The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization, but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. The Company reviews goodwill for impairment annually as of July 31 and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable.

In the first quarter of 2015 the Company revised its reportable segments in connection with the realignment of its portfolio. Specifically, the Company integrated the five existing business divisions into three global divisions, no longer focusing on international as a separate reportable segment but managing each business globally. The change in reportable segments resulted in the Company's requirement to reallocate existing goodwill to the new reportable segments based on the relative fair value of the Company's four underlying reporting units: Specialty Surgical Solutions Instruments, Specialty Surgical Solutions Neurosurgery, Spine, and Orthopedics and Tissue Technologies. Refer to Note 13 - Segment and Geographic Information for more information on the change in reportable segments. With the reportable segments now being managed at a global level, goodwill previously assigned to the EMEA, LAPAC, and Private Label reporting units was reallocated to the new reporting units. The Company estimated the fair value of the four reporting units using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. Inputs used to fair value the Company's reporting units are considered inputs of the fair value hierarchy. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. The key assumptions impacting the valuation included the following:


•	The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans.

•

The projected terminal value for the reporting unit, which represents the present value of projected cash flows beyond the last period in the discounted cash flow analysis. The terminal value reflects the Company's assumptions related to long-term growth rates and profitability, which are based on several factors, including local and macroeconomic variables, market opportunities, and future growth plans.

•

The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise.

Given the excess of the Specialty Surgical Solutions Instruments, Specialty Surgical Solutions Neurosurgery, and Orthopedics and Tissue Technologies estimated fair values over their carrying values after the reallocation of goodwill, no impairment was recognized. The goodwill assigned to the Spine reporting unit was impaired during the first quarter of 2015 and the impairment charge has been presented in the Company's discontinued operations.

In addition to the goodwill impairment testing performed in conjunction with the change in reportable segments, the Company performed its annual goodwill impairment test as of July 31, 2015. In reviewing goodwill for impairment, the Company has the option - for any or all of its reporting units that carry goodwill - to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (i.e. greater than 50%) that the estimated fair value of a reporting unit is less than its carrying amount. If the Company elects to perform a qualitative assessment and determines that an impairment is more likely than not, the Company is then required to perform the two-step quantitative impairment test, otherwise no further analysis is required. The Company also may elect not to perform the qualitative assessment and, instead, proceed directly to step one of the two-step quantitative impairment test. The ultimate outcome of the goodwill impairment review for a reporting unit should be the same whether the Company chooses to perform the qualitative assessment or proceeds directly to the two-step quantitative impairment test.

On July 1, 2015, the Company completed the separation of its spine business, which also represented a reporting unit. See Note 3 - Discontinued Operations for additional information. Following the separation, the Company has three remaining underlying reporting units. The Company elected to perform a two-step quantitative analysis for its three reporting units as of July 31, 2015. To derive the fair value of the reporting units, the Company utilized a discounted cash flow model and inputs and assumptions that were similar to its discounted cash flow model performed in the reallocation of goodwill. The Company determined, after performing the Step-1 fair value analysis, that the reporting units' fair value was in excess of their carrying value; therefore, it was not necessary to proceed to Step-2 of the goodwill impairment test for Specialty Surgical Solutions Instruments, Specialty Surgical Solutions Neurosurgery, and Orthopedics and Tissue Technologies.

Changes in the carrying amount of goodwill in 2015 and 2014 were as follows:



	Specialty Surgical Solutions			Orthopedics and Tissue Technologies			Total
	(In thousands)
Goodwill at December 31, 2014	$	281,829		$	81,650		$	363,479
MicroFrance working capital and purchase price adjustments	(1,069		)	—			(1,069		)
Metasurg working capital and purchase price adjustment	—			263			263
TEI acquisition	—			147,878			147,878
Tekmed acquisition	9,665			—			9,665
Foreign currency translation	(5,449		)	(2,378		)	(7,827		)
Balance, December 31, 2015	$	284,976		$	227,413		$	512,389

When the Company acquires a business, the assets acquired, including IPR&D, and liabilities assumed are recorded at their respective fair values as of the acquisition date. The Company's policy defines IPR&D as the fair value of those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the fair value of intangible assets, including IPR&D, acquired as part of a business combination requires the Company to make significant estimates. These estimates include the amount and timing of projected future cash flows, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks. The fair value assigned to other intangible assets, including IPR&D, is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.

IPR&D acquired in a business combination is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis or accelerated basis, as appropriate, over its estimated useful life. If the R&D project is subsequently abandoned, the indefinite-lived intangible asset is charged to expense. IPR&D acquired outside of a business combination is expensed immediately.

Due to the uncertainty associated with R&D projects, there is risk that actual results will differ materially from the original cash flow projections and that the R&D project will result in a successful commercial product. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, delays or issues with patent issuance, or validity and litigation.

Other intangible assets include patents, trademarks, purchased technology, and supplier and customer relationships. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs over their expected useful lives.

The components of the Company's identifiable intangible assets were as follows:



	Weighted Average Life	December 31, 2015
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	17 years	$	480,684	$	(67,978	)	$	412,706
Customer relationships	12 years	153,246		(68,811		)	84,435
Trademarks/brand names ⁽²⁾	30 years	90,837		(16,374		)	74,463
Supplier relationships	27 years	34,721		(12,236		)	22,485
All other⁽¹⁾	5 years	10,958		(1,307		)	9,651
		$	770,446	$	(166,706	)	$	603,740



	Weighted Average Life	December 31, 2014
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	18 years	$	314,664	$	(46,339	)	$	268,325
Customer relationships	13 years	105,201		(63,689		)	41,512
Trademarks/brand names ⁽²⁾	34 years	44,220		(15,455		)	28,765
Trademarks/brand names ⁽²⁾	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(10,809		)	23,912
All other⁽¹⁾	4 years	2,910		(1,340		)	1,570
		$	550,200	$	(137,632	)	$	412,568


(1)	At December 31, 2015 and 2014, all other included IPR&D of $1.0 million and $1.4 million, respectively, which was indefinite-lived.


(2)	In August 2015, the Company reevaluated the Miltex, CUSA, Luxtec, and Omni-Tract trade names and determined that they are no longer indefinite-lived intangible assets. The Company assigned remaining useful lives ranging from 20 to 30 years, consistent with other trademarks/brand names, and began amortization.

The Company performs its assessment of the recoverability of indefinite-lived intangible assets annually during the second quarter, or more frequently as impairment indicators arise, and it is based upon a comparison of the carrying value of such assets to their estimated fair values. The Company performed its most recent annual assessment during the second quarter of 2015, which resulted in no impairments.

During 2015, the Company recorded impairment charges of $0.4 million in research and development expense related to IPR&D projects that have been discontinued in its Orthopedics and Tissue Technologies segment.

During 2014, the Company recorded impairment charges of $0.2 million in research and development expense related to IPR&D projects primarily acquired in connection with the Metasurg acquisition. In connection with this acquisition, we acquired IPR&D related to a product that will be discontinued. Therefore, a full-impairment of acquired IPR&D was recorded in the Company's selling, general, and administrative expenses. We also recorded an impairment charge of $0.6 million in cost of sales related to acquired technology product rights in conjunction with the Covidien acquisition. Subsequent to the acquisition date, a regulatory event occurred that was not known, or knowable, at the time of acquisition which resulted in the impairment.

During 2013, the Company recorded impairment charges of $0.4 million in research and development expense related to IPR&D projects that have been discontinued in its Orthopedics and Tissue Technologies segment.

Amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired IPR&D) for the years ended December 31, 2015, 2014 and 2013 was $32.2 million, $22.7 million and $11.2 million, respectively. Annual amortization expense is expected to approximate $42.2 million in 2016, $41.5 million in 2017, $40.7 million in 2018, $40.6 million in 2019 and $40.5 million in 2020. Amortization of product technology based intangible assets totaled $22.3 million, $15.9 million and $4.1 million for the years ended December 31, 2015, 2014 and 2013, respectively, and is presented by the Company within cost of goods sold.

LONG-LIVED ASSETS

Long-lived assets held and used by the Company, including property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets.

INTEGRA FOUNDATION

The Company may periodically make contributions to the Integra Foundation, Inc. The Integra Foundation was incorporated in 2002 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the Integra Foundation engages in activities that promote health, the diagnosis and treatment of disease, and the development of medical science through grants, contributions and other appropriate means. The Integra Foundation is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in these consolidated financial statements. The Company contributed $0.9 million, $0.6 million and $0.6 million to the Integra Foundation during the years ended December 31, 2015, 2014 and 2013, respectively. These contributions were recorded in selling, general, and administrative expense.

DERIVATIVES

The Company develops, manufactures, and sells medical devices globally, and its earnings and cash flows are exposed to market risk from changes in interest rates and currency exchange rates. The Company addresses these risks through a risk management program that includes the use of derivative financial instruments, and operates the program pursuant to documented corporate risk management policies. All derivative financial instruments are recognized in the financial statements at fair value in accordance with the authoritative guidance. Under the guidance, for those instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation, based on the exposure being hedged. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. The Company's derivative instruments do not subject its earnings or cash flows to material risk, and gains and losses on these derivatives generally offset losses and gains on the item being hedged. The Company has not entered into derivative transactions for speculative purposes and from time to time, the Company may enter into derivatives that are not designated as hedging instruments in order to protect itself from currency volatility due to intercompany balances.

All derivative instruments are recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments, using the framework prescribed by the authoritative guidance, by considering the estimated amount the Company would receive to sell or transfer these instruments at the reporting date and by taking into account: expected forward interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company utilizes a discounted cash flow model to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The Company has classified all of its derivative assets and liabilities within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of its derivative instruments. The Company classifies derivatives that meet the definition of hedges in the same category as the item being hedged for cash flow presentation purposes.

FOREIGN CURRENCY

All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income (loss). These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries. Foreign currency transaction gains and losses are reported in other income (expense), net.

INCOME TAXES

Income taxes are accounted for by using the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. Reserves are established for positions that don't meet this recognition threshold. The reserve is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. These reserves are classified as long-term liabilities in the consolidated balance sheets of the Company. The Company also records interest and penalties accrued in relation to uncertain tax benefits as a component of income tax expense.

While the Company believes it has identified all reasonably identifiable exposures and the reserve it has established for identifiable exposures is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve.

The Company continues to indefinitely reinvest substantially all of its foreign earnings. Our current analysis indicates that we have sufficient U.S. liquidity, including borrowing capacity, to fund foreseeable U.S. cash needs without requiring the repatriation of foreign cash. As of December 31, 2015, taxes have not been provided on approximately $261.3 million of accumulated foreign unremitted earnings on certain non-US subsidiaries that are expected to remain invested indefinitely. The unrecognized deferred tax liability associated with these temporary differences was estimated to be $37.9 million. One time or unusual items that may impact our ability or intent to keep our foreign earnings and cash indefinitely reinvested include significant U.S. acquisitions, loans from a foreign subsidiary, changes in tax laws.

REVENUE RECOGNITION

Total revenues, net, include product sales, product royalties and other revenues, such as fees received under research, licensing, distribution arrangements, research grants, and technology-related royalties.

Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred; title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured. For product sales, the Company's stated terms are primarily FOB shipping point and with most customers, title and risk of loss pass to the customer at that time. With certain United States customers, the Company retains risk of loss until the customers receive the product, and in those situations, the Company recognizes revenue upon receipt by the customer. A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains title until receiving appropriate notification that the product has been used or implanted, at which time revenue is recognized.

Each revenue transaction is evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. There are generally no significant customer acceptance or other conditions that prevent the Company from recognizing revenue in accordance with its delivery terms. In certain cases, where the Company has performance obligations that are significant to the functionality of the product, the Company recognizes revenue upon fulfillment of its obligation.

Sales invoices issued to customers contain the Company's price for each product or service. The Company performs a review of each specific customer's credit worthiness and ability to pay prior to accepting them as a customer. Further, the Company performs periodic reviews of its customers' status prospectively.

The Company records a provision for estimated returns and allowances on revenues in the same period as the related revenues are recorded. These estimates are based on historical sales returns and discounts and other known factors. The provisions are recorded as a reduction to revenues.

The Company's return policy, as set forth in its product catalogs and sales invoices, requires the Company to review and authorize the return of product in advance. Upon authorization, a credit will be issued for goods returned within a set amount of days from shipment, which is generally ninety days.

Product royalties are estimated and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information and expected sales trends. Differences between actual revenues and estimated royalty revenues are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.

Other operating revenues may include fees received under research, licensing, and distribution arrangements, technology-related royalties and research grants. Non-refundable fees received under research, licensing and distribution arrangements or for the licensing of technology are recognized as revenue when received if the Company has no continuing obligations to the other party. For those arrangements where the Company has continuing performance obligations, revenue is recognized using the lesser of the amount of non-refundable cash received or the result achieved using the proportional performance method of accounting based upon the estimated cost to complete these obligations. Research grant revenue is recognized when the related expenses are incurred.

SHIPPING AND HANDLING FEES AND COSTS

Amounts billed to customers for shipping and handling are included in revenues. The related shipping and freight charges incurred by the Company are included in cost of goods sold. Distribution and handling costs of $13.7 million, $13.2 million and $12.8 million were recorded in selling, general and administrative expense during the years ended December 31, 2015, 2014 and 2013, respectively.

PRODUCT WARRANTIES

Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are reusable and are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from date of purchase. The Company accrues estimated product warranty costs at the time of sale based on historical experience. Any additional amounts are recorded when such costs are probable and can be reasonably estimated. Accrued warranty expense of $0.8 million and $0.3 million is recorded in the consolidated balance sheet at December 31, 2015 and 2014, respectively.

RESEARCH AND DEVELOPMENT

Research and development costs, including salaries, depreciation, consultant and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred.

EMPLOYEE TERMINATION BENEFITS AND OTHER EXIT-RELATED COSTS

The Company does not have a written severance plan, and it does not offer similar termination benefits to affected employees in all restructuring initiatives. Accordingly, in situations where minimum statutory termination benefits must be paid to the affected employees, the Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In all other situations where the Company pays out termination benefits, including supplemental benefits paid in excess of statutory minimum amounts and benefits offered to affected employees based on management's discretion, the Company records these termination costs in accordance with the authoritative guidance for ASC Topic 712 Compensation-Nonretirement Benefits and ASC Topic 420 One-time Employee Termination Benefits.

The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized ratably over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met.

For leased facilities and equipment that have been abandoned, the Company records estimated lease losses based on the fair value of the lease liability, as measured by the present value of future lease payments subsequent to abandonment, less the present value of any estimated sublease income on the cease-use date. For owned facilities and equipment that will be disposed of, the Company records impairment losses based on fair value less costs to sell. The Company also reviews the remaining useful life of long-lived assets following a decision to exit a facility and may accelerate depreciation or amortization of these assets, as appropriate.

STOCK-BASED COMPENSATION

The Company applies the authoritative guidance for stock-based compensation. This guidance requires companies to recognize the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards granted after January 1, 2006 was based on the fair value on the grant date using the binomial distribution model. The Company recognized compensation expense for stock option awards, restricted stock awards, performance stock awards and contract stock awards on a ratable basis over the requisite service period of the award. The long form method was used in the determination of the windfall tax benefit in accordance with the guidance.

PENSION BENEFITS

A defined benefit pension plan covers former employees in Germany. Various factors are considered in determining the pension liability, including the number of employees expected to be paid their salary levels and years of service, the expected return on plan assets, the discount rate used to determine the benefit obligations, the timing of benefit payments and other actuarial assumptions. If the actual results and events for the pension plans differ from current assumptions, the benefit obligation may be over or under valued.

Retirement benefit plan assumptions are reassessed on an annual basis or more frequently if changes in circumstances indicate a re-evaluation of assumptions are required. The key benefit plan assumptions are the discount rate and expected rate of return on plan assets. The discount rate is based on average rates on bonds that matched the expected cash outflows of the benefit plans. The expected rate of return is based on historical and expected returns on the various categories of plan assets.

In September 2015, the Company completed the buy-out of its defined benefit pension plan in the U.K. which covered certain employees and retirees. All plan assets of the defined benefit pension plan were transferred to an independent financial services firm and the Company made cash contributions of approximately $1.8 million for the year-ended December 31, 2015. The Company recorded expenses totaling approximately $5.6 million in selling, general and administrative costs in conjunction with the buy-out of the plan. The buy-out of the U.K. pension plan eliminated future obligations of the Company under this plan.

Pension contributions to the remaining German plan are expected to be consistent over the next few years since the plan is frozen. Contributions made to both the UK and Germany plan during the years ended December 31, 2015, 2014 and 2013 were $2.2 million, $0.9 million and $0.8 million, respectively.

CONCENTRATION OF CREDIT RISK

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions, investment-grade marketable debt securities and trade receivables.

The Company's products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company's trade receivables to customers outside the United States includes sales to foreign distributors, who then sell to government owned or supported healthcare systems.

None of the Company's customers accounted for 10% or more of the consolidated net sales during the years ended December 31, 2015, 2014 and 2013.

RECENTLY ISSUED AND ADOPTED ACCOUNTING STANDARDS

In April 2014, the FASB issued amendments to guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosures for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 . The new guidance is effective for Integra prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after January 1, 2015. The spin-off of the spine business by the Company on July 1, 2015 met the definition of a discontinued operation under the new guidance and, as a result, the Company reflected the provisions of the new guidance in its third quarter 2015 results.

In May 2014, the FASB issued Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should: 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. In July 2015, the FASB deferred for one year the effective date of the new revenue standard, but early adoption will be permitted as of January 1, 2017. The new standard will be effective for the Company on January 1, 2018. The Company is in the process of evaluating the impact of this standard on its financial statements.

In June 2014, the FASB issued Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (Topic 718). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This update is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, and early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on the Company's consolidated financial position or results of operations.

In August 2014, the FASB issued Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendment requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The implementation of the amended guidance is not expected to have an impact on current disclosures in the financial statements.

In April 2015, the FASB issued Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement of debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations and will result in a reclassification of the debt issuance costs from other long-term assets to long-term debt when adopted.

In July 2015, the FASB issued Update No. 2015-11, Simplifying the Measurement of Inventory. The amendment requires an entity to measure inventory that is within the scope of this amendment at the lower of cost and net realizable value. Existing impairment models will continue to be used for inventories that are accounted for using the last-in first-out (“LIFO”) method. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years for public business entities. Early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations.

In August 2015, the FASB issued Update No. 2015-15, Interest - Imputation of Interest. The amendment requires entities to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability. The guidance in ASU No. 2015-03 does not address presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements. Given the absence of authoritative guidance within ASU No. 2015-03 for debt issuance costs related to line-of-credit arrangements, the SEC staff would not object to an entity's deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations.

In September 2015, the FASB issued Update No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments. The amendment requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This update also requires an entity to present separately in the income statement or disclose in the notes, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The new standard must be applied prospectively to adjustments to provisional amounts that occur after the effective date. Early application is permitted for financial statements that have not been issued. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations or disclosures in the financial statements.

In November 2015, the FASB issued Update No. 2015-17, Income Taxes (Topic 740). Under current accounting guidance an entity is required to separate deferred income tax liabilities and assets into current and non-current amounts in a classified statement of financial position. The amendment requires that an entity present all deferred tax assets and liabilities as non-current in a classified statement of financial position. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The Company adopted this guidance effective December 31, 2015 on a prospective basis. As a result, the Company has not retrospectively adjusted the balance sheet classification and presentation for the deferred tax assets and liabilities for years prior to 2015.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

SUPPLEMENTAL CASH FLOW INFORMATION

In addition to the payment of accreted interest associated with the settlement of the 2016 Convertible Notes, cash paid for interest during the years ended December 31, 2015, 2014 and 2013 was $12.7 million (net of $1.7 million that was capitalized into construction in progress), $10.9 million (net of $2.6 million that was capitalized into construction in progress) and $9.5 million (net of $3.2 million that was capitalized into construction in progress), respectively.

Cash paid for income taxes for the years ended December 31, 2015, 2014 and 2013 was $21.3 million, $6.8 million and $3.7 million, respectively.

Property and equipment purchases included in liabilities at December 31, 2015, 2014 and 2013 were $4.7 million, $3.3 million and $8.1 million, respectively.

DISCONTINUED OPERATIONS

12 Months Ended

Dec. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS

On October 29, 2014, Integra's Board of Directors approved the announcement of a plan to separate SeaSpine from Integra as a new, publicly traded medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. Integra's board of directors based this determination, in part, on its belief that the tax-free distribution of SeaSpine shares to Integra stockholders is the most efficient manner to separate our business from Integra's other medical technology businesses. On November 3, 2014, the Company announced its intention to separate its spine business, which was previously a separate reportable segment. On July 1, 2015, the Company completed the distribution of 100% of the outstanding common stock of SeaSpine to Integra stockholders, who received one share of SeaSpine common stock for every three shares of Integra common stock held as of the close of business on the record date, June 19, 2015. The Company and SeaSpine share three board members, including the chair of Integra’s board of directors who is lead director for SeaSpine. The separation agreement ensures that SeaSpine had approximately $47.0 million of total cash immediately following the distribution. No gain or loss was recognized on the part of the Company or shareholders as a result of the distribution resulting from the separation of the spine business.

The historical results of operations, cash flows, and statement of financial position of SeaSpine have been presented as discontinued operations in the consolidated financial statements and prior periods have been revised. Discontinued operations include results of SeaSpine's business except for certain allocated corporate overhead costs and certain costs associated with transition services provided by Integra to SeaSpine. These allocated costs will remain part of continuing operations. Discontinued operations also include other costs incurred by Integra to separate SeaSpine from the fourth quarter of 2014 through the second quarter of 2015. These costs include transaction charges, advisory and consulting fees, and information system expenses. For the third quarter 2015 and going forward, SeaSpine is a stand-alone public company that will separately report its financial results. Due to differences between the basis of presentation for discontinued operations and the basis of presentation as a stand-alone company, the financial results of SeaSpine included within discontinued operations for the Company may not be indicative of actual financial results of SeaSpine as a stand-alone company.

The following table summarizes results from discontinued operations of SeaSpine included in the consolidated statement of operations:



	Years Ended December 31,
	2015			2014			2013
	(in thousands)
Total revenue	$	65,775		$	137,808		$	147,314
Costs and expenses	80,618			140,124			192,843
Operating income (loss)	(14,843		)	(2,316		)	(45,529		)
Other income (expense), net	(766		)	(271		)	(4,559		)
Income (loss) from discontinued operations before tax	(15,609		)	(2,587		)	(50,088		)
Provision (benefit) for income taxes	(5,239		)	(296		)	(6,994		)
Net income (loss) from discontinued operations	$	(10,370	)	$	(2,291	)	$	(43,094	)

No income or expense has been recorded for the SeaSpine business after the separation from Integra on July 1, 2015.

The following table presents Integra's spine business assets and liabilities presented as discontinued operations as of December 31, 2014:



	December 31, 2014
	(in thousands)
Assets:
Cash	$	260
Accounts receivable	21,504
Inventory	47,981
Other current assets	30,040
Current assets of discontinued operations	99,785
Property, plant, and equipment, net	16,360
Intangible assets, net	46,891
Other assets	10,483
Non-current assets of discontinued operations	73,734
Total assets of discontinued operations	$	173,519
Liabilities:
Accounts payable	$	5,193
Accrued compensation	6,300
Accrued expenses and other current liabilities	2,287
Current liabilities of discontinued operations	13,780
Other liabilities	2,631
Long-term liabilities of discontinued operations	2,631
Total liabilities of discontinued operations	$	16,411

The following table presents Integra's spine business assets and liabilities removed from the consolidated balance sheet as of July 1, 2015:



	July 1, 2015
	(in thousands)
Assets:
Cash	$	47,178
Accounts receivable	20,856
Inventory	49,425
Other current assets	13,411
Current assets of discontinued operations	130,870
Property, plant, and equipment, net	21,093
Intangible assets, net	43,122
Other assets	4,465
Non-current assets of discontinued operations	68,680
Total assets of discontinued operations	$	199,550
Liabilities:
Accounts payable	$	7,072
Accrued compensation	5,964
Accrued expenses and other current liabilities	3,361
Current liabilities of discontinued operations	16,397
Deferred tax liabilities	13,331
Other liabilities	2,593
Long-term liabilities of discontinued operations	15,924
Total liabilities of discontinued operations	$	32,321

The removal of SeaSpine's net assets and unrealized accelerated currency translation adjustment is presented as a reduction in Integra's retained earnings and accumulated other comprehensive loss.

In order to effect the separation and govern Integra's relationship with SeaSpine after the separation, the Company entered into a Separation and Distribution Agreement and other agreements including a Tax Matters Agreement, an Employee Matters Agreement, several supply agreements, and a Transition Services Agreement. The Separation and Distribution Agreement governs the separation of the spine business, the transfer of assets and other matters related to the Company's relationship with SeaSpine.

The Tax Matters Agreement governs the respective rights, responsibilities and obligations of SeaSpine and Integra with respect to taxes, tax attributes, tax returns, tax proceedings and certain other tax matters.

The Employee Matters Agreement governs the compensation and employee benefit obligations with respect to the current and former employees and non-employee directors of SeaSpine and Integra, and generally allocates liabilities and responsibilities relating to employee compensation, benefit plans and programs. The Employee Matters Agreement provides that employees of SeaSpine will no longer participate in benefit plans sponsored or maintained by Integra. In addition, the Employee Matters Agreement provides that each of the parties will be responsible for their respective former and current employees and compensation plans for such current employees.

The Company entered into several Supply Agreements in which SeaSpine engaged Integra to be the product supplier of Integra's former Integra Mozaik^TMproduct line ("Mozaik") for a three year period following the separation after which there will be no defined terms and this will be considered a normal purchase/sale arrangement. This product line has been licensed to SeaSpine in conjunction with the spin-off. Prior to the spin-off, the sale of Mozaik products from an Integra facility to a SeaSpine facility eliminated in Integra's historical consolidated financial results of operations. The revenue and cost of goods sold related to prior sales of Mozaik to SeaSpine have been restated and are presented in Integra's continuing operations results of operations. The Company has recorded $6.2 million, $6.2 million, and $7.9 million in revenue related to the sale of Mozaik products for the year-ended December 31, 2015, 2014 and 2013, respectively and $3.8 million, $3.2 million and $5.6 million in cost of goods sold for the year-ended December 31, 2015, 2014 and 2013, respectively, in its continuing operations.

Under the terms of the Transition Services Agreement, the Company agreed to provide administrative, site services, information technology systems and various other corporate and support services to SeaSpine over various periods after the separation on a cost or cost-plus basis. The most significant components of the service income is the provision of IT and legal services which the Company anticipates will be largely completed by the end of the first quarter of 2016. In the year-ended December 31, 2015, other income (expense), net includes $2.7 million of income in respect of the provision of services to SeaSpine.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

+ Details

ACQUISITIONS AND PRO FORMA RESULTS

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

ACQUISITIONS AND PRO FORMA RESULTS

Tekmed

On December 15, 2015, the Company acquired the assets of Tekmed Instruments S.p.A ("Tekmed") for an aggregate purchase price of $14.2 million. Tekmed was a distributor of the Company's products in Italy and has a specialty focus on neurosurgery and neurotrauma, along with representation in plastic and reconstructive surgery, cardiovascular surgery, image diagnostics, general surgery, anesthesia and intensive care, interventional radiology, and proton therapy. This acquisition enables the Company to support Specialty Surgical Solutions growth in Italy along with other key Integra franchises.

The Company recorded revenue for Tekmed of approximately $0.3 million in the consolidated statements of operations for the year-ended December 31, 2015. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it is in the process of being integrated into the Company's operations.

The following summarizes the preliminary allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	1,143
PP&E	669
Other current assets	11
Intangible assets:			Wtd. Avg. Life:
Supplier Contracts	4,981		2 - 13 Years
Goodwill	9,665
Total assets acquired	16,469
Accrued expenses and other liabilities acquired	753
Deferred tax liability	1,564
Net assets acquired	$	14,152

Tornier's United States Toe & Ankle Business

On October 2, 2015, the Company acquired the United States rights to Tornier's Salto Talaris® and Salto Talaris® XT ankle replacement products and Tornier's Futura^TM silastic toe replacement products (the "Salto and Futura") for $6.0 million in cash. The estimated fair value of the net assets acquired exceeded the purchase price for the Salto and Futura product lines and resulted in the Company recording a gain of $1.1 million for the year-ended December 31, 2015 in Other Income. The acquired toe and ankle products enhances the Company's lower extremities product offering and accelerates its entry into the U.S. total ankle replacement market.

The Company recorded revenue for Salto and Futura of approximately $3.6 million in the consolidated statements of operations for the year-ended December 31, 2015. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it is in the process of being integrated into the Company's operations.

The following summarizes the preliminary allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	2,688
Property, plant, and equipment	1,453
Intangible assets:			Life:
Ankle product family	3,210		11 years
Toe product family	460		10 years
Total assets acquired	7,811
Deferred tax liability	700
Net assets acquired	$	7,111

TEI

On July 17, 2015, the Company executed the two merger agreements (collectively, the "Agreements") under which the Company acquired TEI Biosciences, Inc., a Delaware corporation ("TEI Bio"), and TEI Medical Inc., a Delaware corporation ("TEI Med", collectively "TEI") for an aggregate purchase price of approximately $312.4 million ($210.4 million for TEI Bio and $102.0 million for TEI Med) subject in each case to purchase price adjustments for certain working capital changes. The purchase price consists of a cash payment to the former shareholders of TEI Bio and TEI Med of approximately $312.4 million upon the closing of the transaction, net of $1.2 million of acquired cash. The acquired assets includes a contingent receivable with a fair value of $0.4 million and will be paid to the Company if the sale of products used in breast surgery in the United States drops below $6.0 million in either 2016 or 2017. The fair value of this asset is based on future sales projections of the products under various potential scenarios and weighting the probability of these outcomes for the period ended December 31, 2015. At the date of the acquisition, the cash flow projection was discounted using an internal rate of return of 11.0%. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement.

TEI Bio is in the business of developing and commercializing biologic devices for soft tissue repair and regenerative applications, including dura and hernia repair and plastic and reconstructive surgery. TEI Med holds a license to TEI Bio’s regenerative technology in the fields of wound healing and orthopedics.

The Company recorded revenue for TEI of approximately $27.0 million in the consolidated statements of operations for the year-ended December 31, 2015. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it is in the process of being integrated into the Company's operations.

The Company adjusted the preliminary purchase price allocation during the quarter ended December 31, 2015 to reduce deferred tax liabilities by $1.1 million. This adjustment offset goodwill and was the result of the Company analyzing and revising its deferred tax rate. The following summarizes the preliminary allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Cash	$	1,241
Accounts receivable, net	9,011
Inventory	23,223
Property, plant, and equipment	2,027
Income tax receivable	5,135
Other current assets	2,670
Intangible assets:			Wtd. Avg. Life:
Developed technology	167,400		14 - 16 Years
Contractual relationships	51,345		11 - 14 Years
Leasehold interest	69
Goodwill	147,878
Total assets acquired	409,999
Accrued expenses and other liabilities	9,732
Deferred tax liabilities	87,908
Other non-current liabilities	—
Net assets acquired	$	312,359

Metasurg

On December 5, 2014, the Company acquired certain assets of Koby Ventures II, L.P. dba Metasurg ("Metasurg") for an aggregate purchase price of $27.2 million. The purchase price consists of an initial cash payment to Metasurg of $26.5 million and contingent consideration with an acquisition date fair value of $0.7 million. The potential maximum undiscounted contingent consideration of $38.5 million is based on reaching certain sales of acquired products. The fair value of this liability is based on future sales projections of the Metasurg product under various potential scenarios and weighting the probability of these outcomes for the period ended December 31, 2014. At the date of the acquisition, the cash flow projection was discounted using an internal rate of return of 19.9%. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. During the fourth quarter of 2015, the Company adjusted the fair value of the contingent consideration to zero as we no longer believe the achievement of the sales targets is probable. The adjustment was $0.7 million and was recorded in selling, general and administrative expenses.

Metasurg develops intuitive implant systems for the foot and ankle market and sells almost entirely in the U.S. market. The acquired foot and ankle products will enhance the Company's lower extremities market position.

The Company adjusted the preliminary purchase price allocation during the quarter ended June 30, 2015 to reflect the $0.4 million working capital and purchase price adjustment. The following summarizes the final allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	4,800
Property, plant, and equipment	1,246
Intangible assets:			Wtd. Avg. Life:
Technology product rights	20,590		8 - 14 Years
In-process research and development	190		Indefinite
Goodwill	732
Net assets acquired	$	27,558

MicroFrance

On October 27, 2014, the Company acquired all outstanding shares of Medtronic Xomed Instrumentation, SAS ("MicroFrance") from Medtronic, Inc. ("Medtronic") as well as certain assets of Medtronic for $61.6 million in cash. MicroFrance specializes in manual ear, nose, and throat ("ENT") instruments and designs, manufactures, and sells reusable handheld instruments to ENT and laparoscopy surgical specialists around the world. The acquired ENT instruments fill a portfolio gap for the Company with clear growth opportunities through market adjacencies and provides for increased scale and reach in the international market.

The Company adjusted the preliminary purchase price allocation during the quarter ended March 31, 2015 to reflect the $1.5 million working capital and purchase price adjustments. The following summarizes the final allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	2,195
Inventory	3,155
Prepaid expenses	620
Property, plant, and equipment	3,675
Other current assets	5,025
Intangible assets:			Wtd. Avg. Life:
Trade name	11,990		20 Years
Technology	4,580		15 - 16 Years
Customer relationships	18,130		12 - 16 Years
Goodwill	16,607
Total assets acquired	65,977
Accounts payable and other liabilities	5,910
Net assets acquired	$	60,067

Confluent Surgical, Inc.

On January 15, 2014, the Company acquired all outstanding shares of Confluent Surgical, Inc., ("Confluent Surgical") - including its surgical sealant and adhesion barrier product lines - from Covidien Group S.a.r.l, ("Covidien") for an aggregate purchase price of $255.9 million. The purchase price consists of an initial cash payment to Covidien of $231.0 million upon the closing of the transaction, a separate prepayment of $4.0 million made under a transitional supply agreement with an affiliate of Covidien, and contingent consideration with an acquisition date fair value of $20.9 million. The potential maximum undiscounted contingent consideration of $30.0 million consists of $25.0 million upon obtaining certain U.S. governmental approvals and $5.0 million upon obtaining certain European governmental approvals, both related to the completion of the transition of the Confluent Surgical business.

The transitional supply agreement secures the supply of the acquired products from an affiliate of Covidien until the earlier of (i) the time that the transition of the Confluent Surgical business as discussed above is complete, or (ii) the fifth anniversary of the effective date of the agreement (the agreement also contains an option to extend for another two years by providing written notice at least 180 days prior to the end of the initial five-year period). This agreement contains financial incentives to the affiliate of Covidien for the timely supply of products each fiscal quarter through the third anniversary of the agreement. The prices paid under the supply agreement are essentially flat through the third anniversary of the agreement, and then increase significantly each of the following three years. The Company also entered into a transition services agreement with an affiliate of Covidien at the closing for services such as customer service, accounting and information technology management, clinical and regulatory affairs, manufacturing transition services, and other functions.

This acquisition complements the Company's global neurosurgery growth strategy aimed at providing a broader set of solutions for surgical procedures in the head.

The Company recorded revenue for Confluent Surgical of approximately $69.0 million in the consolidated statements of operations from the acquisition date through December 31, 2014. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations.

The Company adjusted the preliminary purchase price allocation during the quarter ended June 30, 2014 to reduce deferred tax liabilities by $12.4 million. This adjustment offset goodwill and was the result of the Company analyzing and revising its tax positions in certain jurisdictions. The following summarizes the final allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Inventory deposit	$	4,000
Property, plant, and equipment	438
Intangible assets:			Wtd. Avg. Life:
Technology product rights	239,800		3 - 20 Years
Other	400
Deferred tax assets - long term	12
Goodwill	105,331
Total assets acquired	349,981
Contingent supply liability	5,891
Other	731
Deferred tax liabilities - long term	87,464
Net assets acquired	$	255,895

Subsequent to the acquisition date, a regulatory event occurred that resulted in the full-impairment of one of the acquired technology product rights of $0.6 million. This event was not known, or knowable, at the time of the acquisition and therefore the impairment has been included in the Company's cost of sales.

The Company accounted for the contingent supply liability by recording its fair value as a liability on the date of the acquisition based on a discounted cash-flow model. This contingent supply liability relates to contractual quarterly incentive payments that will be made to an affiliate of Covidien if certain supply minimums under the transitional supply agreement are met.

The Company accounted for the contingent consideration by recording its fair value as a liability on the date of the acquisition. The contingent consideration relates to the Company's obtaining certain U.S. and European regulatory approvals. At the date of the acquisition, both of these milestones were valued using a discount rate of 2.2%, which is equivalent to the cost of debt for the estimated time horizon, and an overall probability of occurring of 95%. Accordingly, on January 15, 2014 the Company recorded a $20.9 million liability representing the initial fair value estimate of the probability weighted contingent consideration that management believes will be paid between early 2017 and late 2018. Depending on the expected timing of the estimated payments, the acquisition date fair value of the probability adjusted payments could have been $0.3 million higher or $0.4 million lower. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. The contingent consideration is re-measured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings.

Tarsus Medical Inc.

On January 24, 2013, the Company acquired all outstanding preferred and common stock of Tarsus Medical, Inc. ("Tarsus") for a total of $4.7 million consisting of $3.1 million in cash (including working capital adjustments of $0.2 million) and contingent consideration with an estimated acquisition date fair value of approximately $1.6 million. The potential maximum undiscounted contingent consideration consists of a first milestone payment of up to $1.5 million and a second payment of up to $11.5 million. These payments are based on reaching certain sales thresholds of acquired products. During the second quarter of 2014, the Company adjusted the fair value of the contingent consideration to zero as it no longer believed the achievement of the sales targets was probable and the contingent consideration period ended December 31, 2015, with no payment being made. Tarsus is a podiatry device company addressing clinical needs associated with diseases and injuries of the foot and ankle.

The following summarizes the final allocation of the purchase price based on fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	85
Prepaid expenses	13
Intangible assets:			Wtd. Avg. Life:
Technology	5,040		10 - 14 years
In-process research and development	340		Indefinite
Deferred tax asset - long term	1,334
Goodwill	116
Total assets acquired	6,928
Accounts payable and other liabilities	111
Deferred tax liability	2,152
Net assets acquired	$	4,665

Management determined the preliminary fair value of net assets acquired during the first quarter of 2013 and finalized the working capital adjustment in the second quarter of 2013. The Company accounts for the contingent consideration by recording its fair value as a liability on the date of the acquisition and re-measuring the fair value at each reporting date until the contingency is resolved. Changes in fair value of the contingent consideration are recognized in earnings. Accordingly, on January 24, 2013 the Company recorded $1.6 million representing the initial fair value estimate of the contingent consideration that will be earned through December 31, 2015. The fair value of this liability is based on future sales projections of the Tarsus Medical product under various potential scenarios and weighting the probability of these outcomes for the period ended December 31, 2015. At the date of the acquisition, the first milestone cash flow projection was discounted using a rate of 4.3% based on an estimated after tax cost of debt; the second milestone cash flow projection was discounted using a weighted average cost of capital of 16.5%. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement.

The goodwill recorded in connection with these acquisitions is based on (i) expected cost savings, operating synergies and other benefits expected to result from the combined operations, (ii) the value of the going-concern element of the existing business (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately), and (iii) intangible assets that do not qualify for separate recognition such as an assembled workforce. The acquisitions generated a combination of deductible and non-deductible goodwill.

Contingent Consideration

The fair value of contingent consideration during the year-ended December 31, 2015 was increased to reflect current period acquisitions, and the change in the time value of money during the period. A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands):



				Location in Statement of Operations
Balance as of January 1, 2015	$	22,008
Write-off of Metasurg contingent consideration	(650		)	Selling, general, and administrative
Loss from decrease in fair value of contingent consideration liability	473			Selling, general and administrative
Fair value at December 31, 2015	$	21,831

Pro Forma Results (unaudited)

The following unaudited pro forma financial information summarizes the results of operations for the years ended December 31, 2015 and December 31, 2014 as if the acquisitions completed by the Company during 2015 and 2014 had been completed as of the beginning of the prior year. The pro forma results are based upon certain assumptions and estimates, and they give effect to actual operating results prior to the acquisitions and adjustments to reflect (i) increased interest expense, depreciation expense, intangible asset amortization and fair value inventory step-up, (ii) timing of recognition for certain expenses that will not be recurring in the post-acquisition entity, and (iii) income taxes at a rate consistent with the Company’s statutory rate. No effect has been given to other cost reductions or operating synergies. As a result, these pro forma results do not necessarily represent results that would have occurred if the acquisitions had taken place on the basis assumed above, nor are they indicative of the results of future combined operations.

The impact of the Tarsus acquisition is not material to the consolidated operating results of the Company; therefore, the pro-forma impact of the acquisition has not been presented.



	Year Ended December 31,
	2015		2014		2013
	(In thousands except per share amounts)
Total revenue from continuing operations	$	940,005	$	921,998	803,073
Net income from continuing operations	$	10,694	$	40,721	35,796
Net income from continuing operations per share:
Basic	$	0.31	$	1.26	$	1.10

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

DEBT

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

DEBT

Amended and Restated Senior Credit Agreement

On August 28, 2015, the Company entered into a second amendment (the "Second Amendment") to the certain Third Amended and Restated Credit Agreement, dated as of July 2, 2014 among the Company, a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Wells Fargo Bank, National Association, as Syndication Agent, and HSBC Bank USA, National Association, Royal Bank of Canada, Citizens Bank, National Association, DNB Capital LLC, Crédit Agricole-Corporate and Investment Bank, and TD Bank, N.A., as Co-Documentation Agents.

The Second Amendment creates an aggregate principal amount of up to $1.1 billion available to the Company through the following facilities:


i.	a $750.0 million revolving credit facility which includes a $60.0 million sublimit for the issuance of standby letters of credit and a $60.0 million sublimit for swingline loans, and


ii.	a $350.0 million term loan facility.

In connection with the Second Amendment, the Company borrowed $200.0 million of incremental term loans as permitted under the original terms of the Senior Credit Facility to repay a portion of the Company's outstanding revolving loans. Additionally, the Second Amendment (i) enables the Company to incur up to $200.0 million of incremental loans in the future and (ii) modifies the consolidated leverage ratio covenant in the Credit Agreement. The July 2014 amended and restated Senior Credit Facility extended the maturity date of the prior facility from June 8, 2016 to July 2, 2019.

Borrowings under the Senior Credit Facility bear interest, at the Company's option, at a rate equal to:


i.	the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 1.75%), or


ii.	the highest of:


1.	the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%, or


2.	the prime lending rate of Bank of America, N.A., or


3.	the one-month Eurodollar Rate plus 1.00%.

The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness less cash in excess of $40.0 million that is not subject to any restriction of the use or investment thereof to (b) consolidated EBITDA) at the time of the applicable borrowing.

The Company will also pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company’s consolidated total leverage ratio, on the daily amount by which the revolving credit facility exceeds the outstanding loans and letters of credit under the credit facility.

The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at December 31, 2015 the Company was in compliance with all such covenants. The Company capitalized $1.4 million and $3.2 million of incremental financing costs in 2015 and 2014, respectively in connection with the modifications of the Senior Credit Facility and expensed $0.3 million in 2014 of previously capitalized financing costs. No previously capitalized financing costs were expensed in 2015 related to the modification.

At December 31, 2015 and 2014, there was $150.0 million and $266.9 million outstanding, respectively, under the revolving portion of the Senior Credit Facility at a weighted average interest rate of 1.9% and 1.7%, respectively. At December 31, 2015 and 2014 there was $346.2 million and $150.0 million, respectively, outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 1.8% and 1.7%, respectively. At December 31, 2015, there was approximately $600.0 million available for borrowing under the Senior Credit Facility.

The fair value of outstanding borrowings of the Senior Credit Facility's revolving credit facility and term loan components at December 31, 2015 was approximately $139.8 million and $324.9 million, respectively. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities. The Company considers the balance to be long term in nature based on its current intent and ability to repay the borrowing outside of the next twelve-month period.

Contractual repayments of the term loan are due as follows:



Year Ended December 31,	Principal Repayment
	(In thousands)
2016	$14,375
2017	25,625
2018	32,500
2019	273,750
2020	—

2016 Convertible Senior Notes

On June 15, 2011, the Company issued $230.0 million aggregate principal amount of its 1.625% Convertible Senior Notes due 2016 (the “2016 Notes”). The 2016 Notes mature on December 15, 2016, and bear interest at a rate of 1.625% per annum payable semi-annually in arrears on December 15 and June 15 of each year. The portion of the debt proceeds that was classified as equity at the time of the offering was $43.2 million, an equivalent of that amount is being amortized to interest expense using the effective interest method through December 2016. The effective interest rate implicit in the liability component is 5.6%.

At December 31, 2015, the carrying amount of the liability component was $218.7 million, the remaining unamortized discount was $8.4 million, and the principal amount outstanding was $227.1 million. At December 31, 2014, the carrying amount of the liability component was $213.1 million, the remaining unamortized discount was $16.9 million and the principal amount outstanding was $230.0 million.

The fair value of the 2016 Notes at December 31, 2015 was approximately $297.4 million. The fair value of the liability of the 2016 Notes was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair-value hierarchy.

The 2016 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment of 17.4092 shares per $1,000 principal amount of 2016 Notes (which represents an initial conversion price of approximately $57.44 per share). The Company will satisfy any conversion of the 2016 Notes with cash up to the principal amount of the 2016 Notes pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company’s common stock. The 2016 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company’s common stock exceeds 150% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the 2016 Notes is less than or equal to 98% of the average conversion value of the 2016 Notes during a period as defined in the indenture; (3) at any time on or after June 15, 2016; or (4) if specified corporate transactions occur, which included the spin-off of the spine business. The issue price of the 2016 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2016 Notes are not converted. As of March 31, 2015, certain conversion features were triggered due to the announced spin-off of the Company's subsidiary, SeaSpine Holdings Corporation, which allowed the holders to convert all or any of the 2016 Notes subject to certain conditions. The 2016 Notes were convertible through June 10, 2015 and as of the close of the conversion window, note holders provided notice to convert 2,903 notes. During the twelve months ended December 31, 2015, the Company paid $2.9 million in cash and issued 8,457 shares to to settle the obligation to the note holders that converted. As a result of the spin-off and pursuant to the indenture for the Company's 2016 Notes, the initial conversion price and rate was adjusted effective July 1, 2015. The conversion price on the 2016 Notes has been adjusted to $52.83 per share and the new conversion rate is 18.9287 shares per $1,000 principal amount of 2016 Notes. The Company considers the balance to be long term in nature based on its current intent and ability to refinance the borrowing within the next twelve-month period.

In connection with the issuance of the 2016 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of such notes (the “hedge participants”). The initial strike price of the call transaction is approximately $57.44 per share, subject to customary anti-dilution adjustments. The initial strike price of the warrant transaction is approximately $70.05 per share, subject to customary anti-dilution adjustments. The strike price of the call transactions and warrant transactions has been adjusted similarly to the 2016 Notes as a result of the spin-off to $52.83 per share and $64.43 per share, respectively.

Convertible Note Interest

The interest expense components of the Company’s convertible notes are as follows:



	Years Ended December 31,
	2015		2014		2013
	(In thousands)
2016 Notes:
Amortization of the discount on the liability component (1)	$	7,917	$	7,104	$	6,463
Cash interest related to the contractual interest coupon (2)	3,430		3,342		3,218
Total	$	11,347	$	10,446	$	9,681


(1)	The amortization of the discount on the liability component of the 2016 Notes is presented net of capitalized interest of $0.6 million, $0.9 million, and $1.0 million for the years ended December 31, 2015, 2014, and 2013, respectively.


(2)	The cash interest related to the contractual interest coupon on the 2016 Notes is presented net of capitalized interest of $0.3 million, $0.4 million, and $0.5 million for the years ended December 31, 2015, 2014, and 2013, respectively.

DERIVATIVE INSTRUMENTS

12 Months Ended

Dec. 31, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

Interest Rate Hedging

The Company’s interest rate risk relates to U.S. dollar denominated variable LIBOR interest rate borrowings. On August 10, 2015 the interest rate swap derivative instrument the Company entered into on August 20, 2010 with an effective date of December 31, 2010 expired. The interest rate swap was used to manage the Company's earnings and cash flow exposure to changes in interest rates by converting a portion of its floating-rate debt into fixed-rate debt. The Company did not enter into another interest rate swap derivative instruments.

Prior to expiration, the Company designated this derivative instrument as a cash flow hedge. The Company recorded the effective portion of any change in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affected earnings, at which point the effective portion of any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassifed the amount of any gain or loss on the related cash flow hedge to interest expense at that time.

The Company reclassified $0.9 million of pre-tax losses recorded as net in AOCI related to the interest rate hedge to earnings prior to the date of expiration.

Foreign Currency Hedging

From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company records the effective portion of any change in the fair value of foreign currency cash flow hedges in AOCI, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies the effective portion of any related unrealized gain or loss on the foreign currency cash flow hedge to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time.

The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in euros. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect its earnings and cash flows.

Counterparty Credit Risk

The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.

Fair Value of Derivative Instruments

The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair value of the foreign currency forward exchange contracts related to inventory purchases is determined by comparing the forward rate as of the period end and the settlement rate specified in each contract. The fair value of the interest rate swap was developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.

The following table summarizes the fair value, notional amounts presented in U.S. dollars, and presentation in the consolidated balance sheet for derivatives designated as hedging instruments as of December 31, 2015 and December 31, 2014:



	Fair Value as of
	December 31, 2015		December 31, 2014
Location on Balance Sheet ⁽¹⁾:	(In thousands)
Derivatives designated as hedges — Liabilities:
Interest rate swap — Accrued expenses and other current liabilities ⁽²⁾	$	—	$	898
Total Derivatives designated as hedges — Liabilities	$	—	$	898


⁽¹⁾	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.


⁽²⁾	At December 31, 2015 and December 31, 2014, the notional amount related to the Company’s sole interest rate swap was $0.0 million and $97.5 million, respectively.

The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying consolidated statements of operations during the years ended December 31, 2015 and 2014:



	Balance in AOCI Beginning of Year			Amount of Gain (Loss) Recognized in AOCI- (Effective Portion)			Amount of Gain (Loss) Reclassified from AOCI into Earnings-(Effective Portion)			Balance in AOCI End of Year			Location in Statements of Operations
	(In thousands)
Year Ended December 31, 2015
Interest rate swap	$	(898	)	$	(25	)	$	(923	)	$	—		Interest (expense)
	$	(898	)	$	(25	)	$	(923	)	$	—
Year Ended December 31, 2014
Interest rate swap	(2,439		)	(206		)	(1,747		)	(898		)	Interest (expense)
	$	(2,439	)	$	(206	)	$	(1,747	)	$	(898	)

The Company recognized no gains or losses resulting from ineffectiveness of cash flow hedges during the years ended December 31, 2015 and 2014.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Stock-based compensation expense - all related to employees - recognized under the authoritative guidance was as follows:



	Years Ended December 31,
	2015		2014		2013
	(In thousands)
Selling, general and administrative	$	14,461	$	13,940	$	9,484
Research and development	714		463		277
Cost of goods sold	275		151		81
Total stock-based compensation expense	15,450		14,554		9,842
Total estimated tax benefit related to stock-based compensation expense	5,792		5,350		3,806
Net effect on net income	$	9,658	$	9,204	$	6,036

EMPLOYEE STOCK PURCHASE PLAN

The purpose of the Employee Stock Purchase Plan (the “ESPP”) is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan. Under the ESPP, a total of 1.5 million shares of common stock are reserved for issuance. These shares will be made available either from the Company’s authorized but unissued shares of common stock or from shares of common stock reacquired by the Company as treasury shares. At December 31, 2015, 1.0 million shares remain available for purchase under the ESPP. During the years ended December 31, 2015, 2014 and 2013, the Company issued 6,020 shares, 3,889 shares and 4,855 shares under the ESPP for $0.4 million, $0.2 million and $0.2 million, respectively.

EQUITY AWARD PLANS

As of December 31, 2015, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under three plans, the 2000 Equity Incentive Plan (the “2000 Plan”), the 2001 Equity Incentive Plan (the “2001 Plan”), and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, (the “Plans”).

In July 2008 and May 2010, the stockholders of the Company approved amendments to the 2003 Plan to increase by 750,000 and 1,750,000, respectively, the number of shares of common stock that may be issued under the 2003 Plan. The Company has reserved 2,000,000 shares under each of the 2000 Plan and the 2001 Plan, and 6,500,000 shares under the 2003 Plan. The Plans permit the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, contract stock, performance stock, or dividend equivalent rights to designated directors, officers, employees and associates of the Company.

Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers, directors and employees, and generally expire six years from the grant date for employees and from six to ten years for directors and certain executive officers. Restricted stock issued under the Plans vests ratably over specified periods, generally three years after the date of grant.

In connection with the separation of SeaSpine on July 1, 2015 and in accordance with the Employee Matters Agreement, the Company made certain adjustments to the exercise price and number of share-based compensation awards with the intention of preserving the intrinsic value of the awards prior to the separation. Stock options issued in 2015 prior to the separation converted to those of the entity where the employee is working post-separation. Stock options issued prior to 2015 converted to both Integra and SeaSpine options such that the holders received stock options in both companies. The exercise price of these outstanding awards was adjusted to preserve the value of the awards immediately prior to the separation. Performance stock, restricted stock, and contract stock were adjusted for all employees holding outstanding awards to provide holders performance stock, restricted stock, and contract stock in the company that employs such employee following the separation. The adjustments to the Company's stock-based compensation awards resulted in an increase in incremental fair value of $4.4 million, of which $3.3 million was recorded during the year-ended December 31, 2015. The remaining $1.1 million will be recognized prospectively over the remaining term of outstanding awards, adjusted, as applicable, for forfeitures.

Stock Options

The Company values stock option grants using the binomial distribution model. Management believes that the binomial distribution model is preferable to the Black-Scholes model because the binomial distribution model is a more flexible model that considers the impact of non-transferability, and vesting provisions in the valuation of employee stock options.

In determining the value of stock options granted, the Company considered that it has never paid cash dividends and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield. Expected volatilities are based on the historical volatility of the Company’s stock price with forward-looking assumptions. The expected life of stock options is estimated based on historical data on exercise of stock options, post-vesting forfeitures and other factors to estimate the expected term of the stock options granted. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected life of the options. In addition, the Company applies an expected forfeiture rate when amortizing stock-based compensation expenses. The estimate of the forfeiture rates is based primarily upon historical experience of employee turnover. As individual grant awards become fully vested, stock-based compensation expense is adjusted to recognize actual forfeitures.

The following weighted-average assumptions were used in the calculation of fair value:



	Years Ended December 31,
	2015	2014	2013
Dividend yield	0%	0%	0%
Expected volatility	29%	29%	31%
Risk free interest rate	1.96%	2.41%	1.52%
Expected life of option from grant date	8 years	8 years	8 years

The following table summarizes the Company’s stock option activity.



			Weighted Average Exercise Price		Weighted Average Contractual Term in Years	Aggregate Intrinsic Value

	Shares
Stock Options	(In thousands)					(In thousands)
Outstanding at December 31, 2014	1,238		$	39.89
Modification upon spin-off (1)	58		—
Granted	98		62.37
Exercised	(200	)	35.57
Forfeited or Expired	(1	)	53.73
Outstanding at December 31, 2015	1,193		$	37.09	3.26	$	36,614
Vested or expected to vest at December 31, 2015	1,193		$	37.09	3.26	$	36,614
Exercisable at December 31, 2015	1,037		$	35.02	2.69	$	33,980

The intrinsic value of options exercised for the years ended December 31, 2015, 2014 and 2013 were negligible. The weighted average grant date fair value of options granted during the years ended December 31, 2015, 2014 and 2013 was $17.17, $18.15 and $13.86, respectively. Cash received from option exercises was $7.3 million, $15.2 million and $2.3 million, for the years ended December 31, 2015, 2014 and 2013, respectively.

As of December 31, 2015, there was approximately $2.3 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately two years.

Awards of Restricted Stock, Performance Stock and Contract Stock

The following table summarizes the Company’s awards of restricted stock, performance stock and contract stock for the year ended December 31, 2015.



					Performance Stock and Contract Stock Awards
	Restricted Stock Awards				Performance Stock and Contract Stock Awards
	Shares		Weighted Average Grant Date Fair Value Per Share		Shares		Weighted Average Grant Date Fair Value Per Share


	(In thousands)				(In thousands)
Unvested, December 31, 2014	308		$	37.29	283		$	32.74
Modification upon spin-off	42		—		2		—
Surrendered upon spin-off	(3	)	—		—		—
Granted	169		62.32		3		59.52
Cancellations	(56	)	47.79		(1	)	45.46
Released	(166	)	42.48		(121	)	36.51
Unvested, December 31, 2015	294		$	48.20	166		$	33.30

The Company recognized $10.2 million, $13.1 million and $8.6 million in expense related to such awards during the years ended December 31, 2015, 2014 and 2013, respectively. The total fair market value of shares vested in 2015, 2014 and 2013 was $19.9 million, $9.4 million and $6.5 million, respectively.

Performance stock awards have performance features associated with them. Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. The fair value of these awards is being expensed on a straight-line basis over the vesting period. As of December 31, 2015, there was approximately $13.9 million of total unrecognized compensation costs related to unvested awards. These costs are expected to be recognized over a weighted-average period of approximately two years.

At December 31, 2015, there are approximately 0.3 million additional vested Restricted Units held by various employees for which the related shares have not yet been issued.

At December 31, 2015, there were approximately 1.4 million shares available for grant under the Plans.

RETIREMENT BENEFIT PLANS	12 Months Ended
RETIREMENT BENEFIT PLANS	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
RETIREMENT BENEFIT PLANS	RETIREMENT BENEFIT PLANS DEFINED BENEFIT PLANS The Company maintains a defined benefit pension plan that covers employees in its manufacturing plant located in Tuttlingen, Germany (the “Germany Plan”). The Company closed the Tuttlingen, Germany plant in December 2005. The Company did not terminate the Germany Plan, and the Company remains obligated for the accrued pension benefits related to this plan. In September 2015, the Company completed the buy-out of its defined benefit pension plan in the U.K. which covered certain employees and retirees. All plan assets of the defined benefit pension plan were transferred to an independent financial services firm and the Company made cash contributions of approximately $1.8 million for the year-ended December 31, 2015. The Company recorded expenses totaling approximately $5.6 million in selling, general and administrative costs in conjunction with the buy-out of the plan. The buy-out of the U.K. pension plan eliminated future obligations of the Company under this plan. DEFINED CONTRIBUTION PLANS The Company also has various defined contribution savings plans that cover substantially all employees in the United States, the United Kingdom and Puerto Rico. The Company matches a certain percentage of each employee’s contributions as per the provisions of the plans. Total contributions by the Company to the plans were $3.7 million, $3.0 million and $2.9 million for the years ended December 31, 2015, 2014 and 2013, respectively.

LEASES AND RELATED PARTY LEASES

12 Months Ended

Dec. 31, 2015

Leases [Abstract]

LEASES AND RELATED PARTY LEASES

The Company leases administrative, manufacturing, research and distribution facilities and various manufacturing, office and transportation equipment through operating lease agreements. Future minimum lease payments under operating leases at December 31, 2015 were as follows:



	Related Parties		Third Parties		Total
	(In thousands)
2016	$	272	$	9,683	$	9,955
2017	276		7,097		7,373
2018	296		4,427		4,723
2019	296		3,704		4,000
2020	296		1,896		2,192
Thereafter	3,497		18,963		22,460
Total minimum lease payments	$	4,933	$	45,770	$	50,703

Total rental expense for the years ended December 31, 2015, 2014 and 2013 and was $10.1 million, $10.2 million and $10.4 million, respectively, and included $0.3 million, in related party rental expense in each of the three years.

Future minimum lease payments under capital leases at December 31, 2015 were as follows:



	Payments under capital leases (In thousands)
2016	$	672
Total minimum lease payments	672
Amount representing interest	18
Present value of minimum lease payments	$	654

Related Party Leases

The Company leases certain production equipment from a corporation whose sole stockholder is a general partnership, of which the Company’s former Chairman (and current director) is a partner and the President. The term of the lease is through March 31, 2022, and the Company has an option to renew through March 31, 2032. Under the terms of the lease agreement, the Company pays $0.1 million per year to the related party lessor. The Company also leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a corporation whose shareholders are trusts, whose beneficiaries include family members of the Company’s former Chairman (and current director). The term of the current lease agreement is through October 31, 2032 at an annual rate of approximately $0.3 million per year. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2032 through October 31, 2037 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2037 through October 31, 2042 at the fair market rental rate of the premises.

INCOME TAXES

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

Income before income taxes consisted of the following:



	Years Ended December 31,
	2015		2014		2013
	(In thousands)
United States operations	$	37,450	$	21,349	$	6,512
Foreign operations	23,221		24,217		12,274
Total	$	60,671	$	45,566	$	18,786

A reconciliation of the U.S. Federal statutory rate to the Company’s effective tax rate is as follows:



	Years Ended December 31,
	2015		2014		2013
Federal statutory rate	35.0	%	35.0	%	35.0	%
Increase (decrease) in income taxes resulting from:
State income taxes, net of federal tax benefit	1.3	%	5.6	%	0.2	%
Foreign operations	(12.5	)%	(16.7	)%	(27.2	)%
Spine valuation allowance	61.1	%	—	%	—	%
Charitable contributions	(1.0	)%	(2.7	)%	(0.9	)%
Domestic production activities deduction	(2.4	)%	(2.7	)%	—	%
Intercompany profit in inventory	3.1	%	(0.4	)%	(1.4	)%
Nondeductible facilitative costs	3.1	%	1.1	%	—	%
Changes in valuation allowances	0.3	%	2.1	%	1.5	%
Uncertain tax positions	0.2	%	(3.4	)%	(13.8	)%
Research and development credit	(1.9	)%	(1.8	)%	(5.7	)%
Return to provision	1.7	%	1.4	%	(9.8	)%
Other	0.7	%	2.8	%	4.8	%
Effective tax rate	88.7	%	20.3	%	(17.3	)%

The effective tax rate increased by 68.4% in 2015 compared with 2014 primarily due to recording a valuation allowance against net deferred tax assets for the SeaSpine spin-off. The Company recorded an income tax benefit of $0.4 million in the current year for the release of tax contingency reserves as compared to $2.1 million in the prior year. This current year benefit was offset by the establishment of $0.5 million of new tax contingency positions during the year.

During 2015, the Company's foreign operations generated a $2.3 million increase in income tax expense as a result of, among other factors, the geographic and business mix of taxable earnings and losses. The 2015 foreign effective tax rate is 10.6%, an increase of approximately 5.7% over the rate in 2014. The Company's foreign tax rate is primarily based upon statutory rates and is not related to a tax holiday or negotiated tax rate.

During 2014, the Company's foreign operations generated a $1.2 million decrease in income tax expense as a result of, among other factors, the geographic and business mix of taxable earnings and losses and the re-establishment of an income tax benefit in France for half of the year related to intercompany interest. The 2014 foreign effective tax rate is 4.9%, a decrease of approximately 39.6% over the rate in 2013. The Company's foreign tax rate is primarily based upon statutory tax rates and is not related to a tax holiday or negotiated tax rate.

During 2013, the Company's foreign operations generated a $1.0 million increase in income tax expense as a result of, among other factors, the geographic and business mix of taxable earnings and losses and the change of an income tax benefit in France as a result of a French tax law change that occurred on December 30, 2013. The 2013 foreign effective tax rate is 44.5%, an increase of approximately 33.4% over the rate in 2012. The Company's foreign tax rate is primarily based upon statutory tax rates and is not related to a tax holiday or negotiated tax rate.

As of December 31, 2015, the Company has not provided deferred U.S. income taxes or foreign withholding taxes on temporary differences of approximately $261.3 million resulting from earnings for certain non-U.S. subsidiaries which are permanently reinvested outside the U.S. The unrecognized deferred tax liability associated with these temporary differences was estimated to be $37.9 million at December 31, 2015. Events that could trigger a need to repatriate foreign cash to the U.S. and generate a tax might include U.S. acquisitions, loans from a foreign subsidiary, or anticipated tax law changes that are considered unfavorable and would result in higher taxes on repatriations that occur after the change in tax law goes into effect.

The provision for income taxes consisted of the following:



	Years Ended December 31,
	2015			2014			2013
	(In thousands)
Current:
Federal	$	46,665		$	10,330		$	(2,931	)
State	2,301			2,124			399
Foreign	5,205			3,666			632
Total current	$	54,171		$	16,120		$	(1,900	)
Deferred:
Federal	1,282			(5,524		)	(2,409		)
State	(394		)	695			(1,136		)
Foreign	(1,239		)	(2,020		)	2,204
Total deferred	$	(351	)	$	(6,849	)	$	(1,341	)
Provision (benefit) for income taxes	$	53,820		$	9,271		$	(3,241	)

The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below:



	December 31,
	2015		2014
	(In thousands)
Current assets:
Doubtful accounts	$	—	$	1,727
Inventory related items	—		30,017
Tax credits	—		3,156
Accrued vacation	—		3,310
Accrued bonus	—		5,596
Other	—		2,694
Total current deferred tax assets	—		46,500
Less valuation allowance	—		(528		)
Current deferred tax assets after valuation allowance	$	—	$	45,972
Current liabilities:
Other	—		(483		)
Total current deferred tax liabilities	$	—	$	(483	)
Net current deferred tax assets	$	—	$	45,489



	December 31,
	2015			2014
	(In thousands)
Non-current assets:
Doubtful accounts	$	1,943		$	—
Inventory related items	24,417			—
Tax credits	3,137			—
Accrued vacation	2,713			—
Accrued bonus	7,555			—
Stock compensation	16,222			14,840
Deferred revenue	767			3
Net operating loss carryforwards	17,548			17,899
Federal & state tax credits	6,227			12,278
Other	1,952			(402		)
Total non-current deferred tax assets	82,481			44,618
Less valuation allowance	(4,887		)	(6,244		)
Non-current deferred tax assets after valuation allowance	$	77,594		$	38,374
Non-current liabilities:
Intangible & fixed assets	(225,328		)	(148,714		)
Other	(225		)	(665		)
Total non-current deferred tax liabilities	$	(225,553	)	$	(149,379	)
Net non-current deferred tax assets (liabilities)	$	(147,959	)	$	(111,005	)
Total net deferred tax assets (liabilities)	$	(147,959	)	$	(65,516	)

The Company has prospectively adopted Accounting Standards Update 2015-17 to classify all deferred tax assets and liabilities as non-current on the balance sheet. The Company has not retrospectively adjusted the balance sheet classification and presentation herein for the deferred tax assets and liabilities for years prior to 2015.

At December 31, 2015, the Company had net operating loss carryforwards of $34.4 million for federal income tax purposes, $21.7 million for foreign income tax purposes and $14.2 million for state income tax purposes to offset future taxable income. The federal net operating loss carryforwards expire through 2032, $2.9 million of the foreign net operating loss carryforwards expire through 2021 with the remaining $18.8 million having an indefinite carry forward period. The state net operating loss carryforwards expire through 2032.

Deferred tax assets relating to tax benefits of employee stock option grants have been reduced to reflect exercises in 2015. Some exercises have resulted in tax deductions in excess of previously recorded benefits based on the option value at the time of grant (“windfalls”). Although these additional tax benefits are reflected in net operating tax loss carryforwards the additional tax benefit associated with the windfall is not recognized until the deduction reduces taxes payable. Accordingly, since the tax benefit does not reduce our current taxes payable in 2013 due to net operating loss carryforwards, these “windfall” tax benefits are not reflected in our net operating losses in deferred tax assets for 2013.

A valuation allowance of $4.9 million, $6.8 million and $7.3 million is recorded against the Company’s gross deferred tax assets of $82.5 million, $91.1 million, and $91.9 million recorded at December 31, 2015, 2014 and 2013, respectively.

The valuation allowance relates to deferred tax assets for certain items that will be deductible for income tax purposes under very limited circumstances and for which the Company believes it is not more likely than not that it will realize the associated tax benefit. The Company does not anticipate additional income tax benefits through future reductions in the valuation allowance. However, in the event that the Company determines that it would be able to realize more or less than the recorded amount of net deferred tax assets, an adjustment to the deferred tax asset valuation allowance would be recorded in the period such a determination is made.

The Company’s valuation allowance decreased by $1.9 million, and $0.5 million in 2015 and 2014, respectively. The 2015 overall decrease in the valuation allowance was primarily due to expiring net operating losses in the Netherlands which is offset by a reduction in the related deferred tax asset.

A reconciliation of the beginning and ending amount of uncertain tax benefits is as follows:



	Years Ended December 31,
	2015			2014			2013
	(In thousands)
Balance, beginning of year	$	959		$	3,040		$	5,874
Gross increases:
Current year tax positions	—			—			259
Prior years' tax positions	541			527			546
Gross decreases:
Prior years' tax positions	—			(286		)	(476		)
Settlements	—			(828		)	—
Statute of limitations lapses	(404		)	(1,494		)	(3,163		)
Other	(11		)	—			—
Balance, end of year	$	1,085		$	959		$	3,040

Approximately $1.1 million of the balance at December 31, 2015 relates to uncertain tax positions that, if recognized, would affect the annual effective tax rate. Included in the balance of uncertain tax positions at December 31, 2015 is $0.5 million related to tax positions for which it is reasonably possible that the total amounts could be reduced during the twelve months following December 31, 2015, as a result of expiring statutes of limitations.

The Company recognizes interest and penalties relating to uncertain tax positions in income tax expense. The Company recognized a minimal benefit for the year ended December 31, 2015 and a $0.2 million benefit, and a $0.8 million benefit for interest and penalties in the income statement during the years ended December 31, 2014 and 2013, respectively. The Company had minimal interest and penalties accrued at December 31, 2015 and$0.1 million, and $0.4 million of interest and penalties accrued at December 31, 2014 and 2013, respectively.

The Company files Federal income tax returns, as well as multiple state, local and foreign jurisdiction tax returns. The Company is no longer subject to examinations of its Federal income tax returns by the IRS through fiscal year 2011. All significant state and local matters have been concluded through fiscal 2011. All significant foreign matters have been settled through fiscal 2011.

NET (LOSS) INCOME PER SHARE

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

NET (LOSS) INCOME PER SHARE

Basic and diluted net income (loss) per share was as follows:



	Years Ended December 31,
	2015			2014			2013
	(In thousands, except per share amounts)
Basic net (loss) income per share:
Net income from continuing operations	$	6,851		$	36,295		$	22,027
Net loss from discontinued operations	(10,370		)	(2,291		)	(43,094		)
Net (loss) income	$	(3,519	)	$	34,004		$	(21,067	)

Weighted average common shares outstanding	34,495			32,432			28,416

Basic net income per common share from continuing operations	$	0.20		$	1.12		$	0.78
Basic net loss per common share from discontinued operations	(0.30		)	(0.07		)	(1.52		)
Basic net (loss) income per common share	$	(0.10	)	$	1.05		$	(0.74	)

Diluted net income (loss) per share:
Net income from continuing operations	$	6,851		$	36,295		$	22,027
Net loss from discontinued operations	(10,370		)	(2,291		)	(43,094		)
Net (loss) income	$	(3,519	)	$	34,004		$	(21,067	)

Weighted average common shares outstanding — Basic	34,495			32,432			28,416
Effect of dilutive securities:
2016 Convertible notes	461			—			—
Stock options and restricted stock	721			528			386
Weighted average common shares for diluted earnings per share	35,677			32,960			28,802


Diluted net income per common share from continuing operations	$	0.19		$	1.10		$	0.76
Diluted net loss per common share from discontinued operations	(0.29		)	(0.07		)	(1.50		)
Diluted net (loss) income per common share	$	(0.10	)	$	1.03		$	(0.74	)

In connection with the separation of SeaSpine on July 1, 2015 and in accordance with the Employee Matters Agreement, the Company made certain adjustments to the exercise price and number of share-based compensation awards with the intention of preserving the intrinsic value of the awards prior to the separation. Stock options issued in 2015 prior to the separation converted to those of the entity where the employee is working post-separation. Stock options issued prior to 2015 converted to both Integra and SeaSpine options such that the holders received stock options in both companies. The exercise price of these outstanding awards was adjusted to preserve the value of the awards immediately prior to the separation. Performance stock, restricted stock, and contract stock were adjusted to provide holders performance stock, restricted stock, and contract stock in the company that employs such employee following the separation. The adjustments to the Company's stock-based compensation awards resulted in an increase in incremental fair value of $4.4 million, of which $3.3 million was recorded during the year-ended December 31, 2015. The remaining $1.1 million will be recognized prospectively over the remaining term of outstanding awards, adjusted, as applicable, for forfeitures.

Common stock of approximately 0.1 million, 0.2 million and 0.7 million shares at December 31, 2015, 2014 and 2013, respectively, that are issuable through exercise or conversion of dilutive securities were not included in the computation of diluted net income per share because their effect would have been antidilutive. The Company also has warrants outstanding related to its 2016 Notes at December 31, 2015, 2014, and 2013 and the Company's 2016 Notes are convertible to common shares in certain circumstances (see Note 5). These warrants and the excess conversion value of the 2016 Notes are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including such items would be anti-dilutive.

For the year-ended December 31, 2015, the potential excess conversion value on the 2016 Notes was included in the Company's dilutive share calculation because the average stock price for the year-ended December 31, 2015 exceeded the conversion price. For the year-ended December 31, 2014, the potential excess conversion value of the 2016 Notes were anti-dilutive because the conversion price exceeded the Company's stock price; therefore, these amounts have been excluded from the diluted earnings per share calculation.

Performance Shares and Restricted Units that entitle the holders to approximately 0.2 million shares of common stock are included in the basic and diluted weighted average shares outstanding calculation from their date of issuance because no further consideration is due related to the issuance of the underlying common shares.

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in accumulated other comprehensive income (loss) by component between December 31, 2015 and 2014 are presented in the table below, net of tax:



	Gains and Losses on Cash Flow Hedges			Defined Benefit Pension Items			Foreign Currency Items			Total
	(In thousands)
Balance at December 31, 2014	$	(512	)	$	(906	)	$	(22,070	)	$	(23,488	)
Other comprehensive income before reclassifications	(14		)	915			(25,841		)	(24,940		)
Amounts reclassified from accumulated other comprehensive income	526			—			—			526
Current period other comprehensive income (loss)	512			915			(25,841		)	(24,414		)
Balance at December 31, 2015	$	—		$	9		$	(47,911	)	$	(47,902	)

The reclassification adjustments out of accumulated other comprehensive (loss) income during the years ended December 31, 2015 and 2014 is as follows:



Year Ended December 31, 2015
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(923	)	Interest expense
	397			Tax benefit
	$	(526	)	Net of tax



Year Ended December 31, 2014
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(1,747	)	Interest expense
	751			Tax benefit
	$	(996	)	Net of tax

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented. The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on the Company's financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. TEI, a recent acquisition by Integra on July 17, 2015, manufactures a bovine-derived surgical mesh product for Boston Scientific Corporation ("BSC”) and has been named as a defendant in lawsuits under a broad range of products liability theories, many of which have not been served on TEI. Currently, there are approximately fifty active cases against TEI. Pursuant to an indemnification agreement with BSC (i) BSC is managing the litigation; (ii) TEI has in place a products liability insurance policy, of which it must exhaust $3.0 million before BSC’s indemnity begins to cover relevant claims (and of which only a small portion has been utilized to date and against which the insurer has reserved the entire $3.0 million). Because the thrust of products liability litigation focuses on synthetic surgical mesh products, counsel is filing motions to dismiss on behalf of TEI in many cases. In addition, Integra has certain protections in the merger agreements with TEI which would indemnify it for approximately $30.0 million for the first fifteen months after closing and between $20.0 and $30.0 million for the remainder of the three-year period after closing for losses relating to a variety of matters, including half of certain products liability claims (including those related to the product it manufactures for BSC) not covered by insurance. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.

SEGMENT AND GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

In the first quarter of 2015, the Company began to disclose three global reportable segments as a result of changes in how the Company internally manages and reports the results of its businesses to its chief operating decision maker. On July 1, 2015, the Company completed the separation of its spine business, which was a reportable segment. See Note 3 - Discontinued Operations for additional information. Following the separation, the Company is disclosing two reportable segments. The two reportable segments and their activities are described below:

•

The Specialty Surgical Solutions segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 60,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.


•	The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts and nerve and tendon repair.

The most notable change from the Company's financial statements for the year ended December 31, 2014 included in the Annual Report on Form 10-K is the integration of the former International reportable segment into the segments noted above as well as certain products from the Private Label segment into Orthopedics and Tissue Technologies. The Spine Private Label products were included in the separation of the spine business.

The Corporate and other category includes (i) various legal, finance, information systems, executive, and human resource functions, (ii) brand management, and (iii) share-based compensation costs. Prior to the realignment, costs related to procurement, manufacturing operations and logistics for the Company's entire organization were not allocated to operating segments. In connection with the realignment, a portion of these costs have now been incorporated into the disclosed operating segments.

The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the years ended December 31, 2015, 2014 and 2013 are as follows:



	Years Ended December 31,
	2015			2014			2013
	(In thousands)
Segment Net Sales
Specialty Surgical Solutions	$	586,918		$	554,872		$	463,296
Orthopedics and Tissue Technologies	295,816			241,845			233,536
Total revenues	$	882,734		$	796,717		$	696,832
Segment Profit
Specialty Surgical Solutions	$	242,479		$	210,146		$	145,108
Orthopedics and Tissue Technologies	87,844			85,257			72,264
Segment profit	330,323			295,403			217,372
Amortization	(9,953)			(6,810)			(7,099)
Corporate and other	(240,783		)	(220,736		)	(174,900		)
Operating income (loss)	$	79,587		$	67,857		$	35,373

The Company does not allocate any assets to the reportable segments, and, therefore, no asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment.

The Company attributes revenue to geographic areas based on the location of the customer. There are certain revenues managed by the various U.S. segments above that are generated from non-U.S. customers and therefore included in Europe and the Rest of World revenues below.

Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below:



	United States*		Europe		Rest of the World		Consolidated
	(In thousands)
Total revenue, net:
2015	$	680,824	$	103,057	$	98,853	$	882,734
2014	596,303		99,207		101,207		796,717
2013	521,244		85,448		90,140		696,832
Total long-lived assets:
2015	$	192,900	$	19,169	$	1,078	$	213,147
2014	197,897		21,218		1,239		220,354

* Includes long-lived assets in Puerto Rico.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

SELECTED QUARTERLY INFORMATION - UNAUDITED

12 Months Ended

Dec. 31, 2015

Selected Quarterly Financial Information [Abstract]

SELECTED QUARTERLY INFORMATION - UNAUDITED



(In thousands, except per share data)
					Continuing Operations									Net income
Quarter	Total revenue, net		Gross margin		Net income			Per Share - Basic (1)			Per Share - Diluted (1)			Net income			Per Share - Basic (1)			Per Share - Diluted (1)
2015
First	$	202,534	$	127,313	$	11,732		$	0.36		$	0.35		$	8,384		$	0.26		$	0.25
Second	212,673		137,422		12,020			0.36			0.35			4,998			0.15			0.15
Third	226,367		140,298		(31,881		)	(0.90		)	(0.90		)	(31,881		)	(0.90		)	(0.90		)
Fourth	241,160		151,159		14,980			0.41			0.39			14,980			0.41			0.39
	$	882,734	$	556,192	$	6,851								$	(3,519	)

2014
First	$	183,077	$	112,556	$	2,618		$	0.08		$	0.08		$	2,206		$	0.07		$	0.07
Second	197,043		123,538		4,282			0.13			0.13			4,825			0.15			0.15
Third	197,523		123,627		8,990			0.28			0.27			9,807			0.30			0.30
Fourth	219,074		134,050		20,405			0.63			0.62			17,166			0.53			0.52
	$	796,717	$	493,771	$	36,295								$	34,004

(1) Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not necessarily add to the annual amount because of differences in the weighted average common shares outstanding during each period principally due to the effect of the Company’s issuing shares of its common stock during the year.

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Dec. 31, 2015

Valuation and Qualifying Accounts [Abstract]

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS



	Balance at Beginning of Period		Charged to Costs and Expenses			Charged to Other Accounts		Deductions			Balance at End of Period
Description	Balance at Beginning of Period		Charged to Costs and Expenses			Charged to Other Accounts		Deductions			Balance at End of Period
	(In thousands)
Year ended December 31, 2015:
Allowance for doubtful accounts and sales returns and allowances	$	5,659	$	1,262		$	—	$	(1,349	)	$	5,572
Deferred tax asset valuation allowance	6,772		80			—		(1,965		)	4,887
Year ended December 31, 2014:
Allowance for doubtful accounts and sales returns and allowances	$	5,126	2,211			—		(1,678		)	$	5,659
Deferred tax asset valuation allowance	7,283		3			—		(514		)	6,772
Year ended December 31, 2013:
Allowance for doubtful accounts and sales returns and allowances	$	4,837	$	1,292		—		$	(1,003	)	$	5,126
Deferred tax asset valuation allowance	12,213		(5,326		)	—		396			7,283

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Basis Of Presentation

BASIS OF PRESENTATION

Principles Of Consolidation

PRINCIPLES OF CONSOLIDATION

Use Of Estimates

USE OF ESTIMATES

Out of Period Adjustments

OUT OF PERIOD ADJUSTMENTS

Reclassifications

RECLASSIFICATIONS

Certain amounts from the prior years' financial statements have been reclassified in order to conform to the current year's presentation.

Cash And Cash Equivalents

CASH AND CASH EQUIVALENTS

Restricted Cash and Cash Equivalents

RESTRICTED CASH AND CASH EQUIVALENTS

Restricted cash and cash equivalents represents cash that is not available for use in our operations.

Trade Accounts Receivable And Allowances For Doubtful Accounts Receivable

TRADE ACCOUNTS RECEIVABLE AND ALLOWANCES FOR DOUBTFUL ACCOUNTS RECEIVABLE

Inventories

INVENTORIES



	December 31,
	2015		2014
	(In thousands)
Finished goods	$	125,869	$	120,477
Work in process	47,962		38,938
Raw materials	37,598		29,718
Total inventories, net	$	211,429	$	189,133

Property, Plant And Equipment

PROPERTY, PLANT AND EQUIPMENT

Capitalized Interest

CAPITALIZED INTEREST

Goodwill And Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS


•	The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans.

•

Changes in the carrying amount of goodwill in 2015 and 2014 were as follows:



	Specialty Surgical Solutions			Orthopedics and Tissue Technologies			Total
	(In thousands)
Goodwill at December 31, 2014	$	281,829		$	81,650		$	363,479
MicroFrance working capital and purchase price adjustments	(1,069		)	—			(1,069		)
Metasurg working capital and purchase price adjustment	—			263			263
TEI acquisition	—			147,878			147,878
Tekmed acquisition	9,665			—			9,665
Foreign currency translation	(5,449		)	(2,378		)	(7,827		)
Balance, December 31, 2015	$	284,976		$	227,413		$	512,389

The components of the Company's identifiable intangible assets were as follows:



	Weighted Average Life	December 31, 2015
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	17 years	$	480,684	$	(67,978	)	$	412,706
Customer relationships	12 years	153,246		(68,811		)	84,435
Trademarks/brand names ⁽²⁾	30 years	90,837		(16,374		)	74,463
Supplier relationships	27 years	34,721		(12,236		)	22,485
All other⁽¹⁾	5 years	10,958		(1,307		)	9,651
		$	770,446	$	(166,706	)	$	603,740



	Weighted Average Life	December 31, 2014
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	18 years	$	314,664	$	(46,339	)	$	268,325
Customer relationships	13 years	105,201		(63,689		)	41,512
Trademarks/brand names ⁽²⁾	34 years	44,220		(15,455		)	28,765
Trademarks/brand names ⁽²⁾	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(10,809		)	23,912
All other⁽¹⁾	4 years	2,910		(1,340		)	1,570
		$	550,200	$	(137,632	)	$	412,568


(1)	At December 31, 2015 and 2014, all other included IPR&D of $1.0 million and $1.4 million, respectively, which was indefinite-lived.


(2)	In August 2015, the Company reevaluated the Miltex, CUSA, Luxtec, and Omni-Tract trade names and determined that they are no longer indefinite-lived intangible assets. The Company assigned remaining useful lives ranging from 20 to 30 years, consistent with other trademarks/brand names, and began amortization.

LONG-LIVED ASSETS

INTEGRA FOUNDATION

DERIVATIVES

FOREIGN CURRENCY

INCOME TAXES

REVENUE RECOGNITION

Shipping And Handling Fees And Costs

SHIPPING AND HANDLING FEES AND COSTS

Amounts billed to customers for shipping and handling are included in revenues. The related shipping and freight charges incurred by the Company are included in cost of goods sold.

Product Warranties

PRODUCT WARRANTIES

Research And Development

RESEARCH AND DEVELOPMENT

Employee Termination Benefits And Other Exit-Related Costs

EMPLOYEE TERMINATION BENEFITS AND OTHER EXIT-RELATED COSTS

Stock-Based Compensation

STOCK-BASED COMPENSATION

Pension Benefits

PENSION BENEFITS

Concentration Of Credit Risk

CONCENTRATION OF CREDIT RISK

Recently Issued and Adopted Accounting Standards

RECENTLY ISSUED AND ADOPTED ACCOUNTING STANDARDS

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Schedule Of Inventories, Net



	December 31,
	2015		2014
	(In thousands)
Finished goods	$	125,869	$	120,477
Work in process	47,962		38,938
Raw materials	37,598		29,718
Total inventories, net	$	211,429	$	189,133

Schedule Of Property, Plant And Equipment Balances And Corresponding Lives

Property, plant and equipment balances and corresponding lives were as follows:



	December 31,
	2015			2014			Useful Lives
	(In thousands)
Land	$	2,189		$	3,308
Buildings and building improvements	17,611			16,271			5-40 years
Leasehold improvements	75,575			41,154			1-20 years
Machinery and production equipment	103,083			86,010			3-20 years
Surgical instrument kits	15,916			10,758			4-5 years
Information systems and hardware	93,742			90,672			1-7 years
Furniture, fixtures, and office equipment	15,010			14,861			1-15 years
Construction-in-progress	50,571			78,055
Total	373,697			341,089
Less: Accumulated depreciation	(168,516		)	(147,463		)
Property, plant and equipment, net	$	205,181		$	193,626

Schedule Of Changes In Carrying Amount Of Goodwill

Changes in the carrying amount of goodwill in 2015 and 2014 were as follows:



	Specialty Surgical Solutions			Orthopedics and Tissue Technologies			Total
	(In thousands)
Goodwill at December 31, 2014	$	281,829		$	81,650		$	363,479
MicroFrance working capital and purchase price adjustments	(1,069		)	—			(1,069		)
Metasurg working capital and purchase price adjustment	—			263			263
TEI acquisition	—			147,878			147,878
Tekmed acquisition	9,665			—			9,665
Foreign currency translation	(5,449		)	(2,378		)	(7,827		)
Balance, December 31, 2015	$	284,976		$	227,413		$	512,389

Schedule of Finite-Lived Intangible Assets

The components of the Company's identifiable intangible assets were as follows:



	Weighted Average Life	December 31, 2015
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	17 years	$	480,684	$	(67,978	)	$	412,706
Customer relationships	12 years	153,246		(68,811		)	84,435
Trademarks/brand names ⁽²⁾	30 years	90,837		(16,374		)	74,463
Supplier relationships	27 years	34,721		(12,236		)	22,485
All other⁽¹⁾	5 years	10,958		(1,307		)	9,651
		$	770,446	$	(166,706	)	$	603,740



	Weighted Average Life	December 31, 2014
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	18 years	$	314,664	$	(46,339	)	$	268,325
Customer relationships	13 years	105,201		(63,689		)	41,512
Trademarks/brand names ⁽²⁾	34 years	44,220		(15,455		)	28,765
Trademarks/brand names ⁽²⁾	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(10,809		)	23,912
All other⁽¹⁾	4 years	2,910		(1,340		)	1,570
		$	550,200	$	(137,632	)	$	412,568


(1)	At December 31, 2015 and 2014, all other included IPR&D of $1.0 million and $1.4 million, respectively, which was indefinite-lived.


(2)	In August 2015, the Company reevaluated the Miltex, CUSA, Luxtec, and Omni-Tract trade names and determined that they are no longer indefinite-lived intangible assets. The Company assigned remaining useful lives ranging from 20 to 30 years, consistent with other trademarks/brand names, and began amortization.

Schedule of Indefinite-Lived Intangible Assets

The components of the Company's identifiable intangible assets were as follows:



	Weighted Average Life	December 31, 2015
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	17 years	$	480,684	$	(67,978	)	$	412,706
Customer relationships	12 years	153,246		(68,811		)	84,435
Trademarks/brand names ⁽²⁾	30 years	90,837		(16,374		)	74,463
Supplier relationships	27 years	34,721		(12,236		)	22,485
All other⁽¹⁾	5 years	10,958		(1,307		)	9,651
		$	770,446	$	(166,706	)	$	603,740



	Weighted Average Life	December 31, 2014
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in Thousands)
Completed technology	18 years	$	314,664	$	(46,339	)	$	268,325
Customer relationships	13 years	105,201		(63,689		)	41,512
Trademarks/brand names ⁽²⁾	34 years	44,220		(15,455		)	28,765
Trademarks/brand names ⁽²⁾	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(10,809		)	23,912
All other⁽¹⁾	4 years	2,910		(1,340		)	1,570
		$	550,200	$	(137,632	)	$	412,568


(1)	At December 31, 2015 and 2014, all other included IPR&D of $1.0 million and $1.4 million, respectively, which was indefinite-lived.


(2)	In August 2015, the Company reevaluated the Miltex, CUSA, Luxtec, and Omni-Tract trade names and determined that they are no longer indefinite-lived intangible assets. The Company assigned remaining useful lives ranging from 20 to 30 years, consistent with other trademarks/brand names, and began amortization.

DISCONTINUED OPERATIONS (Tables)

12 Months Ended

Dec. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Balance Sheet and Income Statement of Disposal Group

The following table presents Integra's spine business assets and liabilities presented as discontinued operations as of December 31, 2014:



	December 31, 2014
	(in thousands)
Assets:
Cash	$	260
Accounts receivable	21,504
Inventory	47,981
Other current assets	30,040
Current assets of discontinued operations	99,785
Property, plant, and equipment, net	16,360
Intangible assets, net	46,891
Other assets	10,483
Non-current assets of discontinued operations	73,734
Total assets of discontinued operations	$	173,519
Liabilities:
Accounts payable	$	5,193
Accrued compensation	6,300
Accrued expenses and other current liabilities	2,287
Current liabilities of discontinued operations	13,780
Other liabilities	2,631
Long-term liabilities of discontinued operations	2,631
Total liabilities of discontinued operations	$	16,411

The following table summarizes results from discontinued operations of SeaSpine included in the consolidated statement of operations:



	Years Ended December 31,
	2015			2014			2013
	(in thousands)
Total revenue	$	65,775		$	137,808		$	147,314
Costs and expenses	80,618			140,124			192,843
Operating income (loss)	(14,843		)	(2,316		)	(45,529		)
Other income (expense), net	(766		)	(271		)	(4,559		)
Income (loss) from discontinued operations before tax	(15,609		)	(2,587		)	(50,088		)
Provision (benefit) for income taxes	(5,239		)	(296		)	(6,994		)
Net income (loss) from discontinued operations	$	(10,370	)	$	(2,291	)	$	(43,094	)

The following table presents Integra's spine business assets and liabilities removed from the consolidated balance sheet as of July 1, 2015:



	July 1, 2015
	(in thousands)
Assets:
Cash	$	47,178
Accounts receivable	20,856
Inventory	49,425
Other current assets	13,411
Current assets of discontinued operations	130,870
Property, plant, and equipment, net	21,093
Intangible assets, net	43,122
Other assets	4,465
Non-current assets of discontinued operations	68,680
Total assets of discontinued operations	$	199,550
Liabilities:
Accounts payable	$	7,072
Accrued compensation	5,964
Accrued expenses and other current liabilities	3,361
Current liabilities of discontinued operations	16,397
Deferred tax liabilities	13,331
Other liabilities	2,593
Long-term liabilities of discontinued operations	15,924
Total liabilities of discontinued operations	$	32,321

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

+ Details

ACQUISITIONS AND PRO FORMA RESULTS (Tables)

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following summarizes the preliminary allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	1,143
PP&E	669
Other current assets	11
Intangible assets:			Wtd. Avg. Life:
Supplier Contracts	4,981		2 - 13 Years
Goodwill	9,665
Total assets acquired	16,469
Accrued expenses and other liabilities acquired	753
Deferred tax liability	1,564
Net assets acquired	$	14,152

The following summarizes the preliminary allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	2,688
Property, plant, and equipment	1,453
Intangible assets:			Life:
Ankle product family	3,210		11 years
Toe product family	460		10 years
Total assets acquired	7,811
Deferred tax liability	700
Net assets acquired	$	7,111

The following summarizes the preliminary allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Cash	$	1,241
Accounts receivable, net	9,011
Inventory	23,223
Property, plant, and equipment	2,027
Income tax receivable	5,135
Other current assets	2,670
Intangible assets:			Wtd. Avg. Life:
Developed technology	167,400		14 - 16 Years
Contractual relationships	51,345		11 - 14 Years
Leasehold interest	69
Goodwill	147,878
Total assets acquired	409,999
Accrued expenses and other liabilities	9,732
Deferred tax liabilities	87,908
Other non-current liabilities	—
Net assets acquired	$	312,359

Schedule of Assets Acquired and Liabilities Assumed

The following summarizes the final allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	4,800
Property, plant, and equipment	1,246
Intangible assets:			Wtd. Avg. Life:
Technology product rights	20,590		8 - 14 Years
In-process research and development	190		Indefinite
Goodwill	732
Net assets acquired	$	27,558

The following summarizes the final allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	2,195
Inventory	3,155
Prepaid expenses	620
Property, plant, and equipment	3,675
Other current assets	5,025
Intangible assets:			Wtd. Avg. Life:
Trade name	11,990		20 Years
Technology	4,580		15 - 16 Years
Customer relationships	18,130		12 - 16 Years
Goodwill	16,607
Total assets acquired	65,977
Accounts payable and other liabilities	5,910
Net assets acquired	$	60,067

The following summarizes the final allocation of the purchase price as of December 31, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Inventory deposit	$	4,000
Property, plant, and equipment	438
Intangible assets:			Wtd. Avg. Life:
Technology product rights	239,800		3 - 20 Years
Other	400
Deferred tax assets - long term	12
Goodwill	105,331
Total assets acquired	349,981
Contingent supply liability	5,891
Other	731
Deferred tax liabilities - long term	87,464
Net assets acquired	$	255,895

The following summarizes the final allocation of the purchase price based on fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	85
Prepaid expenses	13
Intangible assets:			Wtd. Avg. Life:
Technology	5,040		10 - 14 years
In-process research and development	340		Indefinite
Deferred tax asset - long term	1,334
Goodwill	116
Total assets acquired	6,928
Accounts payable and other liabilities	111
Deferred tax liability	2,152
Net assets acquired	$	4,665

Schedule of Business Acquisitions by Acquisition, Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands):



				Location in Statement of Operations
Balance as of January 1, 2015	$	22,008
Write-off of Metasurg contingent consideration	(650		)	Selling, general, and administrative
Loss from decrease in fair value of contingent consideration liability	473			Selling, general and administrative
Fair value at December 31, 2015	$	21,831

Pro Forma Financial Information, Summary of Results of Operations

The impact of the Tarsus acquisition is not material to the consolidated operating results of the Company; therefore, the pro-forma impact of the acquisition has not been presented.



	Year Ended December 31,
	2015		2014		2013
	(In thousands except per share amounts)
Total revenue from continuing operations	$	940,005	$	921,998	803,073
Net income from continuing operations	$	10,694	$	40,721	35,796
Net income from continuing operations per share:
Basic	$	0.31	$	1.26	$	1.10

DEBT (Tables)

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt

Contractual repayments of the term loan are due as follows:



Year Ended December 31,	Principal Repayment
	(In thousands)
2016	$14,375
2017	25,625
2018	32,500
2019	273,750
2020	—

Components of Interest Expense

The interest expense components of the Company’s convertible notes are as follows:



	Years Ended December 31,
	2015		2014		2013
	(In thousands)
2016 Notes:
Amortization of the discount on the liability component (1)	$	7,917	$	7,104	$	6,463
Cash interest related to the contractual interest coupon (2)	3,430		3,342		3,218
Total	$	11,347	$	10,446	$	9,681


(1)	The amortization of the discount on the liability component of the 2016 Notes is presented net of capitalized interest of $0.6 million, $0.9 million, and $1.0 million for the years ended December 31, 2015, 2014, and 2013, respectively.


(2)	The cash interest related to the contractual interest coupon on the 2016 Notes is presented net of capitalized interest of $0.3 million, $0.4 million, and $0.5 million for the years ended December 31, 2015, 2014, and 2013, respectively.

DERIVATIVE INSTRUMENTS (Tables)

12 Months Ended

Dec. 31, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Summary of Fair Value in Balance Sheet for Derivatives Designated as Hedging Instruments



	Fair Value as of
	December 31, 2015		December 31, 2014
Location on Balance Sheet ⁽¹⁾:	(In thousands)
Derivatives designated as hedges — Liabilities:
Interest rate swap — Accrued expenses and other current liabilities ⁽²⁾	$	—	$	898
Total Derivatives designated as hedges — Liabilities	$	—	$	898


⁽¹⁾	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.


⁽²⁾	At December 31, 2015 and December 31, 2014, the notional amount related to the Company’s sole interest rate swap was $0.0 million and $97.5 million, respectively.

Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations

The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying consolidated statements of operations during the years ended December 31, 2015 and 2014:



	Balance in AOCI Beginning of Year			Amount of Gain (Loss) Recognized in AOCI- (Effective Portion)			Amount of Gain (Loss) Reclassified from AOCI into Earnings-(Effective Portion)			Balance in AOCI End of Year			Location in Statements of Operations
	(In thousands)
Year Ended December 31, 2015
Interest rate swap	$	(898	)	$	(25	)	$	(923	)	$	—		Interest (expense)
	$	(898	)	$	(25	)	$	(923	)	$	—
Year Ended December 31, 2014
Interest rate swap	(2,439		)	(206		)	(1,747		)	(898		)	Interest (expense)
	$	(2,439	)	$	(206	)	$	(1,747	)	$	(898	)

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary Of Employee Stock-Based Compensation Expense

Stock-based compensation expense - all related to employees - recognized under the authoritative guidance was as follows:



	Years Ended December 31,
	2015		2014		2013
	(In thousands)
Selling, general and administrative	$	14,461	$	13,940	$	9,484
Research and development	714		463		277
Cost of goods sold	275		151		81
Total stock-based compensation expense	15,450		14,554		9,842
Total estimated tax benefit related to stock-based compensation expense	5,792		5,350		3,806
Net effect on net income	$	9,658	$	9,204	$	6,036

Summary Of Weighted-Average Assumptions

The following weighted-average assumptions were used in the calculation of fair value:



	Years Ended December 31,
	2015	2014	2013
Dividend yield	0%	0%	0%
Expected volatility	29%	29%	31%
Risk free interest rate	1.96%	2.41%	1.52%
Expected life of option from grant date	8 years	8 years	8 years

Summary Of Stock Option Activity

The following table summarizes the Company’s stock option activity.



			Weighted Average Exercise Price		Weighted Average Contractual Term in Years	Aggregate Intrinsic Value

	Shares
Stock Options	(In thousands)					(In thousands)
Outstanding at December 31, 2014	1,238		$	39.89
Modification upon spin-off (1)	58		—
Granted	98		62.37
Exercised	(200	)	35.57
Forfeited or Expired	(1	)	53.73
Outstanding at December 31, 2015	1,193		$	37.09	3.26	$	36,614
Vested or expected to vest at December 31, 2015	1,193		$	37.09	3.26	$	36,614
Exercisable at December 31, 2015	1,037		$	35.02	2.69	$	33,980

Summary Of Vested And Unvested RSU

The following table summarizes the Company’s awards of restricted stock, performance stock and contract stock for the year ended December 31, 2015.



					Performance Stock and Contract Stock Awards
	Restricted Stock Awards				Performance Stock and Contract Stock Awards
	Shares		Weighted Average Grant Date Fair Value Per Share		Shares		Weighted Average Grant Date Fair Value Per Share


	(In thousands)				(In thousands)
Unvested, December 31, 2014	308		$	37.29	283		$	32.74
Modification upon spin-off	42		—		2		—
Surrendered upon spin-off	(3	)	—		—		—
Granted	169		62.32		3		59.52
Cancellations	(56	)	47.79		(1	)	45.46
Released	(166	)	42.48		(121	)	36.51
Unvested, December 31, 2015	294		$	48.20	166		$	33.30

LEASES AND RELATED PARTY LEASES (Tables)

12 Months Ended

Dec. 31, 2015

Leases [Abstract]

Schedule Of Minimum Lease Payments for Operating Leases

Future minimum lease payments under operating leases at December 31, 2015 were as follows:



	Related Parties		Third Parties		Total
	(In thousands)
2016	$	272	$	9,683	$	9,955
2017	276		7,097		7,373
2018	296		4,427		4,723
2019	296		3,704		4,000
2020	296		1,896		2,192
Thereafter	3,497		18,963		22,460
Total minimum lease payments	$	4,933	$	45,770	$	50,703

Schedule Of Future Minimum Lease Payments for Capital Leases

Future minimum lease payments under capital leases at December 31, 2015 were as follows:



	Payments under capital leases (In thousands)
2016	$	672
Total minimum lease payments	672
Amount representing interest	18
Present value of minimum lease payments	$	654

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References + Details

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Schedule Of Income Before Income Taxes

Income before income taxes consisted of the following:



	Years Ended December 31,
	2015		2014		2013
	(In thousands)
United States operations	$	37,450	$	21,349	$	6,512
Foreign operations	23,221		24,217		12,274
Total	$	60,671	$	45,566	$	18,786

Schedule Of Effective Income Tax Rate Reconciliation

A reconciliation of the U.S. Federal statutory rate to the Company’s effective tax rate is as follows:



	Years Ended December 31,
	2015		2014		2013
Federal statutory rate	35.0	%	35.0	%	35.0	%
Increase (decrease) in income taxes resulting from:
State income taxes, net of federal tax benefit	1.3	%	5.6	%	0.2	%
Foreign operations	(12.5	)%	(16.7	)%	(27.2	)%
Spine valuation allowance	61.1	%	—	%	—	%
Charitable contributions	(1.0	)%	(2.7	)%	(0.9	)%
Domestic production activities deduction	(2.4	)%	(2.7	)%	—	%
Intercompany profit in inventory	3.1	%	(0.4	)%	(1.4	)%
Nondeductible facilitative costs	3.1	%	1.1	%	—	%
Changes in valuation allowances	0.3	%	2.1	%	1.5	%
Uncertain tax positions	0.2	%	(3.4	)%	(13.8	)%
Research and development credit	(1.9	)%	(1.8	)%	(5.7	)%
Return to provision	1.7	%	1.4	%	(9.8	)%
Other	0.7	%	2.8	%	4.8	%
Effective tax rate	88.7	%	20.3	%	(17.3	)%

Schedule Of Provision For Income Taxes

The provision for income taxes consisted of the following:



	Years Ended December 31,
	2015			2014			2013
	(In thousands)
Current:
Federal	$	46,665		$	10,330		$	(2,931	)
State	2,301			2,124			399
Foreign	5,205			3,666			632
Total current	$	54,171		$	16,120		$	(1,900	)
Deferred:
Federal	1,282			(5,524		)	(2,409		)
State	(394		)	695			(1,136		)
Foreign	(1,239		)	(2,020		)	2,204
Total deferred	$	(351	)	$	(6,849	)	$	(1,341	)
Provision (benefit) for income taxes	$	53,820		$	9,271		$	(3,241	)

Schedule Of Deferred Tax Assets And Liabilities

The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below:



	December 31,
	2015		2014
	(In thousands)
Current assets:
Doubtful accounts	$	—	$	1,727
Inventory related items	—		30,017
Tax credits	—		3,156
Accrued vacation	—		3,310
Accrued bonus	—		5,596
Other	—		2,694
Total current deferred tax assets	—		46,500
Less valuation allowance	—		(528		)
Current deferred tax assets after valuation allowance	$	—	$	45,972
Current liabilities:
Other	—		(483		)
Total current deferred tax liabilities	$	—	$	(483	)
Net current deferred tax assets	$	—	$	45,489



	December 31,
	2015			2014
	(In thousands)
Non-current assets:
Doubtful accounts	$	1,943		$	—
Inventory related items	24,417			—
Tax credits	3,137			—
Accrued vacation	2,713			—
Accrued bonus	7,555			—
Stock compensation	16,222			14,840
Deferred revenue	767			3
Net operating loss carryforwards	17,548			17,899
Federal & state tax credits	6,227			12,278
Other	1,952			(402		)
Total non-current deferred tax assets	82,481			44,618
Less valuation allowance	(4,887		)	(6,244		)
Non-current deferred tax assets after valuation allowance	$	77,594		$	38,374
Non-current liabilities:
Intangible & fixed assets	(225,328		)	(148,714		)
Other	(225		)	(665		)
Total non-current deferred tax liabilities	$	(225,553	)	$	(149,379	)
Net non-current deferred tax assets (liabilities)	$	(147,959	)	$	(111,005	)
Total net deferred tax assets (liabilities)	$	(147,959	)	$	(65,516	)

Schedule Of Uncertain Tax Benefits Reconciliation

A reconciliation of the beginning and ending amount of uncertain tax benefits is as follows:



	Years Ended December 31,
	2015			2014			2013
	(In thousands)
Balance, beginning of year	$	959		$	3,040		$	5,874
Gross increases:
Current year tax positions	—			—			259
Prior years' tax positions	541			527			546
Gross decreases:
Prior years' tax positions	—			(286		)	(476		)
Settlements	—			(828		)	—
Statute of limitations lapses	(404		)	(1,494		)	(3,163		)
Other	(11		)	—			—
Balance, end of year	$	1,085		$	959		$	3,040

NET (LOSS) INCOME PER SHARE (Tables)

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Basic And Diluted Net Income (Loss) Per Share

Basic and diluted net income (loss) per share was as follows:



	Years Ended December 31,
	2015			2014			2013
	(In thousands, except per share amounts)
Basic net (loss) income per share:
Net income from continuing operations	$	6,851		$	36,295		$	22,027
Net loss from discontinued operations	(10,370		)	(2,291		)	(43,094		)
Net (loss) income	$	(3,519	)	$	34,004		$	(21,067	)

Weighted average common shares outstanding	34,495			32,432			28,416

Basic net income per common share from continuing operations	$	0.20		$	1.12		$	0.78
Basic net loss per common share from discontinued operations	(0.30		)	(0.07		)	(1.52		)
Basic net (loss) income per common share	$	(0.10	)	$	1.05		$	(0.74	)

Diluted net income (loss) per share:
Net income from continuing operations	$	6,851		$	36,295		$	22,027
Net loss from discontinued operations	(10,370		)	(2,291		)	(43,094		)
Net (loss) income	$	(3,519	)	$	34,004		$	(21,067	)

Weighted average common shares outstanding — Basic	34,495			32,432			28,416
Effect of dilutive securities:
2016 Convertible notes	461			—			—
Stock options and restricted stock	721			528			386
Weighted average common shares for diluted earnings per share	35,677			32,960			28,802


Diluted net income per common share from continuing operations	$	0.19		$	1.10		$	0.76
Diluted net loss per common share from discontinued operations	(0.29		)	(0.07		)	(1.50		)
Diluted net (loss) income per common share	$	(0.10	)	$	1.03		$	(0.74	)

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) by component between December 31, 2015 and 2014 are presented in the table below, net of tax:



	Gains and Losses on Cash Flow Hedges			Defined Benefit Pension Items			Foreign Currency Items			Total
	(In thousands)
Balance at December 31, 2014	$	(512	)	$	(906	)	$	(22,070	)	$	(23,488	)
Other comprehensive income before reclassifications	(14		)	915			(25,841		)	(24,940		)
Amounts reclassified from accumulated other comprehensive income	526			—			—			526
Current period other comprehensive income (loss)	512			915			(25,841		)	(24,414		)
Balance at December 31, 2015	$	—		$	9		$	(47,911	)	$	(47,902	)

Reclassification out of Accumulated Other Comprehensive Income

The reclassification adjustments out of accumulated other comprehensive (loss) income during the years ended December 31, 2015 and 2014 is as follows:



Year Ended December 31, 2015
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(923	)	Interest expense
	397			Tax benefit
	$	(526	)	Net of tax



Year Ended December 31, 2014
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(1,747	)	Interest expense
	751			Tax benefit
	$	(996	)	Net of tax

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Schedule Of Net Sales And Operating Income By Reportable Segment

Net sales and profit by reportable segment for the years ended December 31, 2015, 2014 and 2013 are as follows:



	Years Ended December 31,
	2015			2014			2013
	(In thousands)
Segment Net Sales
Specialty Surgical Solutions	$	586,918		$	554,872		$	463,296
Orthopedics and Tissue Technologies	295,816			241,845			233,536
Total revenues	$	882,734		$	796,717		$	696,832
Segment Profit
Specialty Surgical Solutions	$	242,479		$	210,146		$	145,108
Orthopedics and Tissue Technologies	87,844			85,257			72,264
Segment profit	330,323			295,403			217,372
Amortization	(9,953)			(6,810)			(7,099)
Corporate and other	(240,783		)	(220,736		)	(174,900		)
Operating income (loss)	$	79,587		$	67,857		$	35,373

Schedule of Segment Reporting Information, by Segment

Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below:



	United States*		Europe		Rest of the World		Consolidated
	(In thousands)
Total revenue, net:
2015	$	680,824	$	103,057	$	98,853	$	882,734
2014	596,303		99,207		101,207		796,717
2013	521,244		85,448		90,140		696,832
Total long-lived assets:
2015	$	192,900	$	19,169	$	1,078	$	213,147
2014	197,897		21,218		1,239		220,354

* Includes long-lived assets in Puerto Rico.

SELECTED QUARTERLY INFORMATION - UNAUDITED (Tables)

12 Months Ended

Dec. 31, 2015

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Information



(In thousands, except per share data)
					Continuing Operations									Net income
Quarter	Total revenue, net		Gross margin		Net income			Per Share - Basic (1)			Per Share - Diluted (1)			Net income			Per Share - Basic (1)			Per Share - Diluted (1)
2015
First	$	202,534	$	127,313	$	11,732		$	0.36		$	0.35		$	8,384		$	0.26		$	0.25
Second	212,673		137,422		12,020			0.36			0.35			4,998			0.15			0.15
Third	226,367		140,298		(31,881		)	(0.90		)	(0.90		)	(31,881		)	(0.90		)	(0.90		)
Fourth	241,160		151,159		14,980			0.41			0.39			14,980			0.41			0.39
	$	882,734	$	556,192	$	6,851								$	(3,519	)

2014
First	$	183,077	$	112,556	$	2,618		$	0.08		$	0.08		$	2,206		$	0.07		$	0.07
Second	197,043		123,538		4,282			0.13			0.13			4,825			0.15			0.15
Third	197,523		123,627		8,990			0.28			0.27			9,807			0.30			0.30
Fourth	219,074		134,050		20,405			0.63			0.62			17,166			0.53			0.52
	$	796,717	$	493,771	$	36,295								$	34,004

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)			1 Months Ended	3 Months Ended			6 Months Ended	12 Months Ended
	Jul. 31, 2015 Segment	Jul. 01, 2015 shares	Aug. 31, 2015	Mar. 31, 2015 Segment	Sep. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2015 USD ($) Customer Segment	Dec. 31, 2014 USD ($) Customer Segment	Dec. 31, 2013 USD ($) Customer
Summary Of Significant Accounting Policies [Line Items]
Tax benefit								$ (53,820,000)	$ (9,271,000)	$ 3,241,000
Restricted cash and cash equivalents								4,073,000	0
Inventory, capitalized expenses								0	0
Depreciation expense								27,000,000	23,700,000	19,900,000
Interest expense capitalized to property, plant, and equipment								$ 1,700,000	$ 2,600,000
Number of reportable segments \| Segment	3			3				2	5
Number of reportable segments, goodwill reallocated \| Segment								4
Goodwill, impairment loss								$ 0
Impairment of indefinite-lived Assets							$ 0
Amortization expense								32,200,000	$ 22,700,000	11,200,000
Annual amortization expense expected to approximate in 2015								42,200,000
Annual amortization expense expected to approximate in 2016								41,500,000
Annual amortization expense expected to approximate in 2017								40,700,000
Annual amortization expense expected to approximate in 2018								40,600,000
Annual amortization expense expected to approximate in 2019								40,500,000
Charitable contributions								900,000	600,000	600,000
Undistributed earnings of foreign subsidiaries								261,300,000
Amount of unrecognized deferred tax liability								37,900,000
Distribution and handling costs								$ 13,700,000	13,200,000	12,800,000
Extended warranties, in years								2 years
Accrued warranty expense								$ 800,000	300,000
Defined benefit plan, contributions by employer								1,800,000
Defined benefit plan, recognized net gain (loss) due to settlements and curtailments								(5,600,000)
Pension contributions								2,200,000	900,000	800,000
Interest paid								12,700,000	10,900,000	9,500,000
Interest paid, capitalized								1,700,000	2,600,000	3,200,000
Income taxes paid								21,300,000	6,800,000	3,700,000
Capital expenditures incurred but not yet paid								4,700,000	3,300,000	8,100,000
In-process research and development
Summary Of Significant Accounting Policies [Line Items]
Other Indefinite-lived intangible assets								1,000,000	1,400,000
Impairment charges								$ 400,000	$ 200,000	400,000
Trademarks Brand Names
Summary Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life								30 years	34 years
Technology
Summary Of Significant Accounting Policies [Line Items]
Amortization expense, included in cost of product revenues								$ 22,300,000	$ 15,900,000	$ 4,100,000
Computer Equipment
Summary Of Significant Accounting Policies [Line Items]
Capital leased assets, gross								2,000,000
Capital leases, lessee balance sheet, assets by major class, accumulated depreciation								$ 1,300,000	$ 700,000
Out-of-period Adjustment
Summary Of Significant Accounting Policies [Line Items]
Tax benefit						$ 1,000,000
Sales Revenue, Net
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage								10.00%	10.00%	10.00%
Concentration risk, number of customers over benchmark \| Customer								0	0	0
Deferred tax accounts in 2011 error \| Out-of-period Adjustment
Summary Of Significant Accounting Policies [Line Items]
Tax benefit						$ 900,000
Confluent Surgical, Inc.
Summary Of Significant Accounting Policies [Line Items]
Impairment of finite-lived assets					$ 600,000			$ 600,000
SeaSpine Inc. \| Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Summary Of Significant Accounting Policies [Line Items]
Disposal group, including discontinued operation, distribution of spinoff shares, percent		100.00%
Disposal group, including discontinued operation, shares required for issuance of spinoff share \| shares		3
Minimum \| Trademarks Brand Names
Summary Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			20 years
Maximum \| Trademarks Brand Names
Summary Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			30 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Changes in Accounting Estimate) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Provision (benefit) for income taxes		$ 53,820	$ 9,271	$ (3,241)
Out-of-period Adjustment
Income Statement [Abstract]
Provision (benefit) for income taxes	$ (1,000)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Inventories, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Finished goods	$ 125,869	$ 120,477
Work-in process	47,962	38,938
Raw materials	37,598	29,718
Inventories, net	$ 211,429	$ 189,133

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Property, Plant And Equipment Balances And Corresponding Lives) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 373,697	$ 341,089
Less: Accumulated depreciation	(168,516)	(147,463)
Property, plant and equipment, net	205,181	193,626
Land
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	2,189	3,308
Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 17,611	16,271
Buildings and building improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Buildings and building improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	40 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 75,575	41,154
Leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	1 year
Leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	20 years
Machinery and production equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 103,083	86,010
Machinery and production equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Machinery and production equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	20 years
Surgical instrument kits
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 15,916	10,758
Surgical instrument kits \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	4 years
Surgical instrument kits \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Information systems and hardware
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 93,742	90,672
Information systems and hardware \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	1 year
Information systems and hardware \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Furniture, fixtures, and office equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 15,010	14,861
Furniture, fixtures, and office equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	1 year
Furniture, fixtures, and office equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	15 years
Construction-in-progress
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 50,571	$ 78,055

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Goodwill And Other Intangible Assets [Line Items]
Goodwill	$ 363,479
Goodwill [Roll Forward]
Goodwill, beginning of period	363,479
Foreign currency translation	(7,827)
Goodwill, end of period	512,389
Medtronic MicroFrance
Goodwill And Other Intangible Assets [Line Items]
Goodwill, purchase accounting adjustments	(1,069)
Goodwill	16,607
Goodwill [Roll Forward]
Goodwill, beginning of period	16,607
Metasurg
Goodwill And Other Intangible Assets [Line Items]
Goodwill, purchase accounting adjustments	263
Goodwill	732
Goodwill [Roll Forward]
Goodwill, end of period	732
TEI Biosciences Inc and TEI Medical Inc.
Goodwill And Other Intangible Assets [Line Items]
Goodwill	147,878
Goodwill [Roll Forward]
Goodwill acquired during the period	147,878
Goodwill, end of period	147,878
Tekmed
Goodwill And Other Intangible Assets [Line Items]
Goodwill	9,665
Goodwill [Roll Forward]
Goodwill acquired during the period	9,665
Goodwill, end of period	9,665
Specialty Surgical Solutions
Goodwill And Other Intangible Assets [Line Items]
Goodwill	281,829
Goodwill [Roll Forward]
Goodwill, beginning of period	281,829
Foreign currency translation	(5,449)
Goodwill, end of period	284,976
Specialty Surgical Solutions \| Medtronic MicroFrance
Goodwill And Other Intangible Assets [Line Items]
Goodwill, purchase accounting adjustments	(1,069)
Specialty Surgical Solutions \| Metasurg
Goodwill And Other Intangible Assets [Line Items]
Goodwill, purchase accounting adjustments	0
Specialty Surgical Solutions \| TEI Biosciences Inc and TEI Medical Inc.
Goodwill [Roll Forward]
Goodwill acquired during the period	0
Specialty Surgical Solutions \| Tekmed
Goodwill [Roll Forward]
Goodwill acquired during the period	9,665
Orthopedics and Tissue Technologies
Goodwill And Other Intangible Assets [Line Items]
Goodwill	81,650
Goodwill [Roll Forward]
Goodwill, beginning of period	81,650
Foreign currency translation	(2,378)
Goodwill, end of period	227,413
Orthopedics and Tissue Technologies \| Medtronic MicroFrance
Goodwill And Other Intangible Assets [Line Items]
Goodwill, purchase accounting adjustments	0
Orthopedics and Tissue Technologies \| Metasurg
Goodwill And Other Intangible Assets [Line Items]
Goodwill, purchase accounting adjustments	263
Orthopedics and Tissue Technologies \| TEI Biosciences Inc and TEI Medical Inc.
Goodwill [Roll Forward]
Goodwill acquired during the period	147,878
Orthopedics and Tissue Technologies \| Tekmed
Goodwill [Roll Forward]
Goodwill acquired during the period	$ 0

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Components Of Company's Identifiable Intangible Assets) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Goodwill And Other Intangible Assets [Line Items]
Accumulated amortization		$ (166,706)	$ (137,632)
Finite and indefinite-lived intangible assets, cost		770,446	550,200
Finite and indefinite-lived assets, net		$ 603,740	$ 412,568
Completed Technology
Goodwill And Other Intangible Assets [Line Items]
Weighted average life, years		17 years	18 years
Finite-lived intangible assets, cost		$ 480,684	$ 314,664
Accumulated amortization		(67,978)	(46,339)
Finite-lived intangible assets, net		$ 412,706	$ 268,325
Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Weighted average life, years		12 years	13 years
Finite-lived intangible assets, cost		$ 153,246	$ 105,201
Accumulated amortization		(68,811)	(63,689)
Finite-lived intangible assets, net		$ 84,435	$ 41,512
Trademarks Brand Names
Goodwill And Other Intangible Assets [Line Items]
Weighted average life, years		30 years	34 years
Finite-lived intangible assets, cost		$ 90,837	$ 44,220
Accumulated amortization		(16,374)	(15,455)
Finite-lived intangible assets, net		$ 74,463	$ 28,765
Supplier Relationships
Goodwill And Other Intangible Assets [Line Items]
Weighted average life, years		27 years	27 years
Finite-lived intangible assets, cost		$ 34,721	$ 34,721
Accumulated amortization		(12,236)	(10,809)
Finite-lived intangible assets, net		$ 22,485	$ 23,912
All Other
Goodwill And Other Intangible Assets [Line Items]
Weighted average life, years		5 years	4 years
Finite-lived intangible assets, cost		$ 10,958	$ 2,910
Accumulated amortization		(1,307)	(1,340)
Finite-lived intangible assets, net		9,651	1,570
In-process research and development
Goodwill And Other Intangible Assets [Line Items]
Other indefinite-lived intangible assets		$ 1,000	1,400
Minimum \| Trademarks Brand Names
Goodwill And Other Intangible Assets [Line Items]
Weighted average life, years	20 years
Maximum \| Trademarks Brand Names
Goodwill And Other Intangible Assets [Line Items]
Weighted average life, years	30 years
Trademarks Brand Names Miltex, CUSA, Luxtec, and Omni-Tract
Goodwill And Other Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)			$ 48,484

DISCONTINUED OPERATIONS - Summary of Statements of Operations, Discontinued Operations (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income (loss) from discontinued operations		$ (10,370,000)	$ (2,291,000)	$ (43,094,000)
SeaSpine Inc. \| Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue	$ 65,775,000		137,808,000	147,314,000
Costs and expenses	80,618,000		140,124,000	192,843,000
Operating income (loss)	(14,843,000)		(2,316,000)	(45,529,000)
Other income (expense), net	(766,000)		(271,000)	(4,559,000)
Income (loss) from discontinued operations before tax	(15,609,000)		(2,587,000)	(50,088,000)
Provision (benefit) for income taxes	(5,239,000)		(296,000)	(6,994,000)
Net income (loss) from discontinued operations	$ (10,370,000)	$ 0	$ (2,291,000)	$ (43,094,000)

DISCONTINUED OPERATIONS - Summary of Assets and Liabilities, Discontinued Operations (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Jul. 01, 2015	Dec. 31, 2014	Oct. 29, 2014
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Current assets of discontinued operations	$ 0		$ 99,785
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Non-current assets of discontinued operations	0		73,734
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Current liabilities of discontinued operations	0		13,780
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Long-term liabilities of discontinued operations	$ 0		2,631
SeaSpine Inc. \| Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Cash		$ 47,178	260	$ 47,000
Accounts receivable		20,856	21,504
Inventory		49,425	47,981
Other current assets		13,411	30,040
Current assets of discontinued operations		130,870	99,785
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Property, plant, and equipment, net		21,093	16,360
Intangible assets, net		43,122	46,891
Other assets		4,465	10,483
Non-current assets of discontinued operations		68,680	73,734
Total assets of discontinued operations		199,550	173,519
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Accounts payable		7,072	5,193
Accrued compensation		5,964	6,300
Accrued expenses and other current liabilities		3,361	2,287
Current liabilities of discontinued operations		16,397	13,780
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Deferred tax liabilities		13,331
Other liabilities		2,593	2,631
Long-term liabilities of discontinued operations		15,924	2,631
Total liabilities of discontinued operations		$ 32,321	$ 16,411

DISCONTINUED OPERATIONS - Narrative (Details)		9 Months Ended	12 Months Ended
DISCONTINUED OPERATIONS - Narrative (Details)	Jul. 01, 2015 USD ($) director shares	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Oct. 29, 2014 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations, net of tax			$ (10,370,000)	$ (2,291,000)	$ (43,094,000)
SeaSpine Inc. \| Supply Commitment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue			6,200,000	6,200,000	7,900,000
Discontinued operation, intra-entity amounts, discontinued operation after disposal, expense			3,800,000	3,200,000	5,600,000
SeaSpine Inc. \| Information Technology and Administrative Support
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue			2,700,000
SeaSpine Inc. \| Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, including discontinued operation, distribution of spinoff shares, percent	100.00%
Disposal group, including discontinued operation, shares required for issuance of spinoff share \| shares	3
Disposal group, including discontinued operation, cash and cash equivalents	$ 47,178,000			260,000		$ 47,000,000
Disposal group, including discontinued operation, (gain) loss			0
Loss from discontinued operations, net of tax		$ (10,370,000)	$ 0	$ (2,291,000)	$ (43,094,000)
Director \| SeaSpine Inc. \| Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Related party, shared management, number of common employees \| director	3

ACQUISITIONS AND PRO FORMA RESULTS (Narrative) (Details)								3 Months Ended				9 Months Ended	12 Months Ended
	Dec. 15, 2015 USD ($)	Oct. 02, 2015 USD ($)	Jul. 17, 2015 USD ($) acquisition	Dec. 05, 2014 USD ($)	Oct. 27, 2014 USD ($)	Jan. 15, 2014 USD ($)	Jan. 24, 2013 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2014 USD ($) intangible_asset	Jun. 30, 2014 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Business Acquisition [Line Items]
Business combination, bargain purchase, gain recognized, amount													$ 1,111,000	$ 0	$ 0
Number of businesses acquired \| acquisition			2
Payments to acquire businesses, net of cash acquired													328,888,000	320,921,000	$ 2,980,000
Business combination, contingent consideration, liability								$ 21,831,000					21,831,000	22,008,000
Tekmed
Business Acquisition [Line Items]
Consideration transferred	$ 14,200,000
Revenue since acquisition date													300,000
Net assets acquired								14,152,000					14,152,000
Salto and Futura
Business Acquisition [Line Items]
Revenue since acquisition date													3,600,000
Payments to acquire business		$ 6,000,000
Net assets acquired								7,111,000					7,111,000
TEI
Business Acquisition [Line Items]
Consideration transferred			$ 312,400,000
Revenue since acquisition date													27,000,000
Payments to acquire businesses, net of cash acquired			312,400,000
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents			1,241,000
Business combination, contingent consideration, asset			400,000
Business combination, contingent consideration, asset, revenue threshold to realize asset			$ 6,000,000
Discount rate			11.00%
TEI \| Deferred Tax Liability
Business Acquisition [Line Items]
Goodwill adjustments								1,100,000
TEI Biosciences Inc.
Business Acquisition [Line Items]
Consideration transferred			$ 210,400,000
TEI Medical Inc.
Business Acquisition [Line Items]
Consideration transferred			$ 102,000,000
Metasurg
Business Acquisition [Line Items]
Consideration transferred				$ 27,200,000
Payments to acquire business				26,500,000
Business combination, contingent consideration, liability				700,000				0					0
Contingent consideration arrangements, maximum payout				$ 38,500,000
Discount rate				19.90%
Adjustment on consideration transferred									$ 400,000
Net assets acquired								27,558,000					27,558,000
Goodwill adjustments													263,000
Medtronic MicroFrance
Business Acquisition [Line Items]
Payments to acquire business					$ 61,600,000
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents														2,195,000
Adjustment on consideration transferred												$ 1,500,000
Net assets acquired														60,067,000
Goodwill adjustments													(1,069,000)
Confluent Surgical, Inc.
Business Acquisition [Line Items]
Revenue since acquisition date														$ 69,000,000
Business combination, contingent consideration, liability						$ 20,900,000
Contingent consideration arrangements, maximum payout						$ 30,000,000
Discount rate						2.20%
Net assets acquired						$ 255,900,000		255,895,000					255,895,000
Payment for business interest						231,000,000
Payments for transitional supply agreement						$ 4,000,000
Arrangement extension period						2 years
Required number of days for extension						180 days
Period of contingent consideration arrangement						5 years
Period of transitional supply price increases						3 years
Number of assets impaired \| intangible_asset										1
Impairment of finite-lived assets										$ 600,000			600,000
Probability of event						95.00%
Incremental increase in liability						$ 300,000
Incremental decrease in liability						400,000
Confluent Surgical, Inc. \| Deferred Tax Liability
Business Acquisition [Line Items]
Goodwill adjustments											$ 12,400,000
Confluent Surgical, Inc. \| Cash Consideration One
Business Acquisition [Line Items]
Contingent consideration arrangements, maximum payout						25,000,000
Confluent Surgical, Inc. \| Cash Consideration Two
Business Acquisition [Line Items]
Contingent consideration arrangements, maximum payout						$ 5,000,000
Tarsus Medical, Inc.
Business Acquisition [Line Items]
Payments to acquire business							$ 4,700,000
Payments to acquire businesses, net of cash acquired							3,100,000
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents							85,000
Business combination, contingent consideration, liability							1,600,000	0					0
Contingent consideration arrangements, maximum payout							11,500,000.0
Adjustment on consideration transferred							200,000
Net assets acquired							4,665,000
Contingent consideration, low estimate							$ 1,500,000.0
Tarsus Medical, Inc. \| Cash Consideration One
Business Acquisition [Line Items]
Discount rate							4.30%
Tarsus Medical, Inc. \| Cash Consideration Two
Business Acquisition [Line Items]
Discount rate							16.50%
Other Income \| Salto and Futura
Business Acquisition [Line Items]
Business combination, bargain purchase, gain recognized, amount													$ 1,100,000
Selling, general and administrative \| Metasurg
Business Acquisition [Line Items]
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability								$ 700,000

ACQUISITIONS AND PRO FORMA RESULTS (Schedule of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands					12 Months Ended
	Oct. 02, 2015	Dec. 05, 2014	Oct. 27, 2014	Jan. 24, 2013	Dec. 31, 2015	Dec. 31, 2014	Jan. 15, 2014
Business Acquisition [Line Items]
Goodwill					$ 512,389	$ 363,479
TEI Biosciences Inc and TEI Medical Inc.
Business Acquisition [Line Items]
Cash					1,241
Accounts receivable, net					9,011
Inventory					23,223
Property, plant, and equipment					2,027
Income tax receivable					5,135
Other current assets					2,670
Goodwill					147,878
Total assets acquired					409,999
Accrued expenses and other liabilities					9,732
Deferred tax liabilities					87,908
Other non-current liabilities					0
Net assets acquired					312,359
TEI Biosciences Inc and TEI Medical Inc. \| Developed Technology
Business Acquisition [Line Items]
Intangible assets					167,400
TEI Biosciences Inc and TEI Medical Inc. \| Contractual Relationships
Business Acquisition [Line Items]
Intangible assets					51,345
TEI Biosciences Inc and TEI Medical Inc. \| Leasehold interest
Business Acquisition [Line Items]
Intangible assets					69
Metasurg
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 26,500
Inventory					4,800
Property, plant, and equipment					1,246
Goodwill					732
Net assets acquired					27,558
Metasurg \| Technology
Business Acquisition [Line Items]
Intangible assets					20,590
Medtronic MicroFrance
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross			$ 61,600
Cash						2,195
Inventory						3,155
Property, plant, and equipment						3,675
Other current assets						5,025
Goodwill						16,607
Total assets acquired						65,977
Prepaid expenses						620
Accounts payable and other liabilities						5,910
Net assets acquired						60,067
Medtronic MicroFrance \| Technology
Business Acquisition [Line Items]
Intangible assets						4,580
Medtronic MicroFrance \| Trade names
Business Acquisition [Line Items]
Intangible assets						11,990
Medtronic MicroFrance \| Customer Relationships
Business Acquisition [Line Items]
Intangible assets						$ 18,130
Confluent Surgical, Inc.
Business Acquisition [Line Items]
Property, plant, and equipment					438
Goodwill					105,331
Total assets acquired					349,981
Other non-current liabilities					731
Prepaid expenses					4,000
Contingent supply liability					5,891
Deferred tax liability					87,464
Deferred tax assets - long term					12
Net assets acquired					255,895		$ 255,900
Confluent Surgical, Inc. \| Developed Technology
Business Acquisition [Line Items]
Intangible assets					239,800
Confluent Surgical, Inc. \| Other
Business Acquisition [Line Items]
Intangible assets					400
Tarsus Medical, Inc.
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross				$ 4,700
Cash				85
Goodwill				116
Total assets acquired				6,928
Prepaid expenses				13
Accounts payable and other liabilities				111
Deferred tax liability				2,152
Deferred tax assets - long term				1,334
Net assets acquired				4,665
Tarsus Medical, Inc. \| Technology
Business Acquisition [Line Items]
Intangible assets				5,040
Tekmed
Business Acquisition [Line Items]
Inventory					1,143
Property, plant, and equipment					669
Other current assets					11
Goodwill					9,665
Total assets acquired					16,469
Accrued expenses and other liabilities					753
Deferred tax liabilities					1,564
Net assets acquired					14,152
Tekmed \| Supplier Contracts
Business Acquisition [Line Items]
Intangible assets					4,981
Salto and Futura
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 6,000
Inventory					2,688
Property, plant, and equipment					1,453
Total assets acquired					7,811
Deferred tax liabilities					700
Net assets acquired					7,111
Salto and Futura \| Ankle product family
Business Acquisition [Line Items]
Intangible assets					$ 3,210
Wtd. Avg. Life:					11 years
Salto and Futura \| Toe product family
Business Acquisition [Line Items]
Intangible assets					$ 460
Wtd. Avg. Life:					10 years
In-process research and development \| Metasurg
Business Acquisition [Line Items]
In-process research and development					$ 190
In-process research and development \| Tarsus Medical, Inc.
Business Acquisition [Line Items]
In-process research and development				$ 340
Maximum \| TEI Biosciences Inc and TEI Medical Inc. \| Developed Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:					16 years
Maximum \| TEI Biosciences Inc and TEI Medical Inc. \| Contractual Relationships
Business Acquisition [Line Items]
Wtd. Avg. Life:					14 years
Maximum \| Metasurg \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:					14 years
Maximum \| Medtronic MicroFrance \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:						16 years
Maximum \| Medtronic MicroFrance \| Trade names
Business Acquisition [Line Items]
Wtd. Avg. Life:						20 years
Maximum \| Medtronic MicroFrance \| Customer Relationships
Business Acquisition [Line Items]
Wtd. Avg. Life:						16 years
Maximum \| Confluent Surgical, Inc. \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:						20 years
Maximum \| Tarsus Medical, Inc. \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:				14 years
Maximum \| Tekmed \| Supplier Contracts
Business Acquisition [Line Items]
Wtd. Avg. Life:					13 years
Minimum \| TEI Biosciences Inc and TEI Medical Inc. \| Developed Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:					14 years
Minimum \| TEI Biosciences Inc and TEI Medical Inc. \| Contractual Relationships
Business Acquisition [Line Items]
Wtd. Avg. Life:					11 years
Minimum \| Metasurg \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:					8 years
Minimum \| Medtronic MicroFrance \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:						15 years
Minimum \| Medtronic MicroFrance \| Customer Relationships
Business Acquisition [Line Items]
Wtd. Avg. Life:						12 years
Minimum \| Confluent Surgical, Inc. \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:						3 years
Minimum \| Tarsus Medical, Inc. \| Technology
Business Acquisition [Line Items]
Wtd. Avg. Life:				10 years
Minimum \| Tekmed \| Supplier Contracts
Business Acquisition [Line Items]
Wtd. Avg. Life:					2 years

ACQUISITIONS AND PRO FORMA RESULTS (Roll Forward of Contingent Consideration Liability for Purchase of Tarsus Medical) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Business Acquisition, Contingent Consideration [Roll Forward]
Beginning of Period	$ 22,008
Ending of Period	21,831
Metasurg
Business Acquisition, Contingent Consideration [Roll Forward]
Ending of Period	0
Selling, general and administrative
Business Acquisition, Contingent Consideration [Roll Forward]
Loss from decrease in fair value of contingent consideration liability	473
Selling, general and administrative \| Metasurg
Business Acquisition, Contingent Consideration [Roll Forward]
Loss from decrease in fair value of contingent consideration liability	$ (650)

ACQUISITIONS AND PRO FORMA RESULTS (Pro Forma Financial Information Summarization Results of Operations) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Combinations [Abstract]
Total revenue from continuing operations	$ 940,005	$ 921,998	$ 803,073
Net income from continuing operations	$ 10,694	$ 40,721	$ 35,796
Net income per share
Basic (in dollars per share)	$ 0.31	$ 1.26	$ 1.10

DEBT (Narrative) (Details)				12 Months Ended
DEBT (Narrative) (Details)	Aug. 28, 2015 USD ($)	Jul. 02, 2015 $ / shares	Jul. 02, 2014 USD ($)	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Jun. 10, 2015 convertible_debt_instrument	Jun. 15, 2011 USD ($)
Debt Instrument [Line Items]
Amortization of debt issuance costs				$ 2,264,000	$ 2,571,000	$ 2,298,000
Carrying amount of liability				218,720,000	213,121,000
July 2014 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			$ 1,100,000,000
Cash balance threshold above which excess amount is not subject to any restriction of use or investment			40,000,000
Capitalized incremental financing costs			3,200,000	1,400,000
Amortization of debt issuance costs			$ 300,000	0
July 2014 Amendment \| Minimum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage			0.15%
July 2014 Amendment \| Maximum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage			0.30%
Senior Credit Facility
Debt Instrument [Line Items]
Line of credit facility outstanding				$ 150,000,000	$ 266,900,000
Weighted average interest rate on debt				1.90%	1.70%
Available borrowings under senior secured revolving credit facility				$ 600,000,000
Fair value of outstanding borrowings				139,800,000
2016 Convertible Senior Notes
Debt Instrument [Line Items]
Fair value of outstanding borrowings				297,400,000
Principal amount outstanding				227,097,000	$ 230,000,000			$ 230,000,000
Interest rate on debt								1.625%
Portion of the debt proceeds that was classified as equity at the time of the offering								$ 43,200,000
Debt Instrument, interest rate, effective percentage								5.60%
Carrying amount of liability				218,700,000	213,100,000
Unamortized discount				$ 8,400,000	16,900,000
Common stock based on initial conversion rate ratio (in shares)				17.4092
Principal amount to be considered for conversion purpose				$ 1,000
Initial conversion price, per share \| $ / shares				$ 57.44
Maximum selling price of company's common stock				150.00%
Principal amount of notes per average trading price				$ 1,000
Maximum average conversion value of the notes				98.00%
Earliest conversion date				June 15, 2016
Strike price of the call transaction (in dollars per share) \| $ / shares				$ 57.44
Strike price of warrant transactions (in dollars per share) \| $ / shares				$ 70.05
Amortization of debt discount (premium), interest costs capitalized				$ 600,000	900,000	1,000,000
Interest expense, debt, excluding amortization, interest costs capitalized				$ 300,000	$ 400,000	$ 500,000
Revolving Credit Facility \| July 2014 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			$ 750,000,000
Standby Letters of Credit \| July 2014 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			60,000,000
Swingline Loan \| July 2014 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			60,000,000
Term Loan
Debt Instrument [Line Items]
Weighted average interest rate on debt				1.80%	1.70%
Term loan, amount outstanding				$ 346,200,000	$ 150,000,000
Fair value of outstanding borrowings				324,900,000
Term Loan \| July 2014 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			$ 350,000,000
Term Loan \| August Two Thousand Fifteen Amendment
Debt Instrument [Line Items]
Proceeds from lines of credit	$ 200,000,000
Convertible Debt
Debt Instrument [Line Items]
Common stock based on initial conversion rate ratio (in shares)		18.9287
Initial conversion price, per share \| $ / shares		$ 52.83
Debt instrument, convertible, number of debt instruments pending conversion \| convertible_debt_instrument							2,903
Repayments of debt				$ 2,900,000
Stock issued during period, shares, conversion of convertible securities \| shares				8,457
Strike price of the call transaction (in dollars per share) \| $ / shares		52.83
Strike price of warrant transactions (in dollars per share) \| $ / shares		$ 64.43
Eurodollar \| July 2014 Amendment \| Minimum
Debt Instrument [Line Items]
Interest rates available to the company at its option			1.00%
Eurodollar \| July 2014 Amendment \| Maximum
Debt Instrument [Line Items]
Interest rates available to the company at its option			1.75%
Federal Funds \| July 2014 Amendment
Debt Instrument [Line Items]
Interest rates available to the company at its option			0.50%
(LIBOR) \| July 2014 Amendment
Debt Instrument [Line Items]
Interest rates available to the company at its option			1.00%

DEBT (Schedule of Debt Maturity) (Details) - Term Loan $ in Thousands	Dec. 31, 2015 USD ($)
Debt Instrument [Line Items]
2016	$ 14,375
2017	25,625
2018	32,500
2019	273,750
2020	$ 0

DEBT (Components of Interest Expense) (Details) - 2016 Convertible Senior Notes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Amortization of the discount on the liability component	$ 7,917	$ 7,104	$ 6,463
Cash interest related to the contractual interest coupon	3,430	3,342	3,218
Total	11,347	10,446	9,681
Amortization of debt discount, capitalized interest	600	900	1,000
Cash interest related to contractual interest coupon, capitalized interest	$ 300	$ 400	$ 500

DERIVATIVE INSTRUMENTS (Narrative) (Details) - USD ($)	12 Months Ended
DERIVATIVE INSTRUMENTS (Narrative) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Derivative [Line Items]
Gain (Loss) on ineffectiveness	$ 0	$ 0
Interest rate swap
Derivative [Line Items]
Pretax losses expected to be reclassified from AOCI in next 12 months	$ 900,000

DERIVATIVE INSTRUMENTS (Summary of Fair Value in Balance Sheet for Derivatives Designated Hedging Instruments) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Derivative fair value of derivative liability	$ 0	$ 898
Interest rate swap
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Derivative, Notional Amount	0	97,500
Interest rate swap \| Accrued expenses and other current liabilities
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Derivative fair value of derivative liability	$ 0	$ 898

DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance in AOCI Beginning of Year	$ (898)	$ (2,439)
Amount of Gain (Loss) Recognized in AOCI- (Effective Portion)	(25)	(206)
Amount of Gain (Loss) Reclassified from AOCI into Earnings-(Effective Portion)	(923)	(1,747)
Balance in AOCI End of Year	0	(898)
Interest (expense) \| Interest rate swap
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance in AOCI Beginning of Year	(898)	(2,439)
Amount of Gain (Loss) Recognized in AOCI- (Effective Portion)	(25)	(206)
Amount of Gain (Loss) Reclassified from AOCI into Earnings-(Effective Portion)	(923)	(1,747)
Balance in AOCI End of Year	$ 0	$ (898)

TREASURY STOCK (Narrative) (Details) - USD ($)	12 Months Ended
TREASURY STOCK (Narrative) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Oct. 28, 2014
Accelerated Share Repurchases [Line Items]
Repurchase of common stock, shares	0	0
2014 Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Stock repurchase authorized amount			$ 75,000,000
Amount available for share repurchase under this latest authorization	$ 75,000,000

STOCK-BASED COMPENSATION (Narrative) (Details) $ / shares in Units, $ in Thousands		1 Months Ended		6 Months Ended	12 Months Ended
	Jul. 01, 2015 USD ($)	May. 31, 2010 shares	Jul. 31, 2008 shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 USD ($) stock_based_compensation_plan $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for purchase (in shares) \| shares				1,400,000	1,400,000
Number of stock-based compensation plans \| stock_based_compensation_plan					3
Dividend yield					0.00%	0.00%	0.00%
Weighted average grant date fair value of options granted (in dollars per share) \| $ / shares					$ 17.17	$ 18.15	$ 13.86
Cash received from option exercises					$ 7,300	$ 15,200	$ 2,300
Share-based compensation expense recognized					$ 15,450	14,554	9,842
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable for officers, directors and employees, vesting period, in years					4 years
Stock options exercisable for directors, expiration period, in years					6 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable for employees, expiration period, in years					6 years
Stock options exercisable for directors, expiration period, in years					10 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period for cost recognition, in years					2 years
Total unrecognized compensation costs related to unvested awards				$ 2,300	$ 2,300
Restricted Stock, Performance Stock and Contract Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period for cost recognition, in years					2 years
Total unrecognized compensation costs related to unvested awards				$ 13,900	$ 13,900
Share-based compensation expense recognized					10,200	13,100	8,600
Fair value of shares vested					$ 19,900	$ 9,400	$ 6,500
Requisite service periods of performance stock, restricted stock and contract stock awards, in years					3 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					3 years
Restricted Stock Units (RSUs) \| Non Former Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non issued vested restricted stock units (in shares) \| shares				300,000	300,000
2000 and 2001 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares) \| shares				2,000,000	2,000,000
2003 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares) \| shares				6,500,000	6,500,000
Increase in authorized shares (in shares) \| shares		1,750,000	750,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares) \| shares				1,500,000	1,500,000
Shares available for purchase (in shares) \| shares				1,000,000	1,000,000
Shares issued (in shares) \| shares					6,020	3,889	4,855
ESPP proceeds received					$ 400	$ 200	$ 200
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff \| SeaSpine Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, plan modification, incremental compensation cost	$ 4,400
Total unrecognized compensation costs related to unvested awards				$ 1,100	1,100
Share-based compensation expense recognized				$ 3,300	$ 3,300

STOCK-BASED COMPENSATION (Summary Of Employee Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 15,450	$ 14,554	$ 9,842
Total estimated tax benefit related to stock-based compensation expense	5,792	5,350	3,806
Net effect on net income	9,658	9,204	6,036
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	14,461	13,940	9,484
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	714	463	277
Cost of goods sold
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 275	$ 151	$ 81

STOCK-BASED COMPENSATION (Summary Of Weighted-Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	29.00%	29.00%	31.00%
Risk free interest rate	1.96%	2.41%	1.52%
Expected life of option from grant date	8 years	8 years	8 years

STOCK-BASED COMPENSATION (Summary Of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share, Outstanding at beginning of year \| shares	1,238
Shares, Modification upon spin-off \| shares	58
Shares, Granted \| shares	98
Shares, Exercised \| shares	(200)
Shares, Forfeited or Expired \| shares	(1)
Shares, Outstanding at end of year \| shares	1,193
Shares, Vested or expected to vest at end of year \| shares	1,193
Shares, Exercisable at end of year \| shares	1,037
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Outstanding at beginning of year \| $ / shares	$ 39.89
Weighted Average Exercise Price, Modification Upon Spin-off \| $ / shares	0.00
Weighted Average Exercise Price, Granted \| $ / shares	62.37
Weighted Average Exercise Price, Exercised \| $ / shares	35.57
Weighted Average Exercise Price, Forfeited or Expired \| $ / shares	53.73
Weighted Average Exercise Price, Outstanding at end of year \| $ / shares	37.09
Weighted Average Exercise Price, Exercisable at end of year \| $ / shares	$ 35.02
Weighted Average Contractual Term in Years, Outstanding at end of year	3 years 3 months 4 days
Weighted Average Contractual Term in Years, Vested or expected to vest at end of year	3 years 3 months 4 days
Weighted Average Contractual Term in Years, Exercisable at end of year	2 years 8 months 9 days
Weighted Average Exercise Price, Vested or expected to vest at end of year \| $ / shares	$ 37.09
Aggregate Intrinsic Value, Outstanding at end of year \| $	$ 36,614
Aggregate Intrinsic Value, Vested or expected to vest at end of year \| $	36,614
Aggregate Intrinsic Value, Exercisable at end of year \| $	$ 33,980

STOCK-BASED COMPENSATION (Summary Of Vested And Unvested RSU) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2015 $ / shares shares
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value Per Share, Unvested beginning balance \| $ / shares	$ 37.29
Weighted Average Grant Date Fair Value Per Share, Modification Upon Spin-off \| $ / shares	0.00
Weighted Average Grant Date Fair Value Per Share, Surrendered Upon Spin-off \| $ / shares	0.00
Weighted Average Grant Date Fair Value Per Share, Granted \| $ / shares	62.32
Weighted Average Grant Date Fair Value Per Share, Cancellations \| $ / shares	47.79
Weighted Average Grant Date Fair Value Per Share, Unvested ending balance \| $ / shares	$ 48.20
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Unvested beginning balance \| shares	308
Shares, Modification Upon Spin-off \| shares	42
Shares, Surrendered Upon Spin-off \| shares	3
Shares, Granted \| shares	169
Shares, Cancellations \| shares	(56)
Shares, Unvested ending balance, shares \| shares	294
Performance Stock and Contract Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value Per Share, Unvested beginning balance \| $ / shares	$ 32.74
Weighted Average Grant Date Fair Value Per Share, Modification Upon Spin-off \| $ / shares	0.00
Weighted Average Grant Date Fair Value Per Share, Surrendered Upon Spin-off \| $ / shares	0.00
Weighted Average Grant Date Fair Value Per Share, Granted \| $ / shares	59.52
Weighted Average Grant Date Fair Value Per Share, Cancellations \| $ / shares	45.46
Weighted Average Grant Date Fair Value Per Share, Unvested ending balance \| $ / shares	$ 33.30
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Unvested beginning balance \| shares	283
Shares, Modification Upon Spin-off \| shares	2
Shares, Surrendered Upon Spin-off \| shares	0
Shares, Granted \| shares	3
Shares, Cancellations \| shares	(1)
Shares, Unvested ending balance, shares \| shares	166
Released \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value Per Share, Released \| $ / shares	$ 42.48
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Released \| shares	(166)
Released \| Performance Stock and Contract Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value Per Share, Released \| $ / shares	$ 36.51
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Released \| shares	(121)

RETIREMENT BENEFIT PLANS (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Defined benefit plan, contributions by employer	$ 1.8
Defined benefit plan, recognized net gain (loss) due to settlements and curtailments	5.6
Total contributions made by the Company	$ 3.7	$ 3.0	$ 2.9

LEASES AND RELATED PARTY LEASES (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Leased Assets [Line Items]
Total rental expense	$ 10.1	$ 10.2	$ 10.4
Related Party
Operating Leased Assets [Line Items]
Total rental expense	$ 0.3	$ 0.3	$ 0.3
Term of lease	March 31, 2022
Option to renew lease	March 31, 2032
Payment per year to related party lessor	$ 0.1
Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former chairman	50.00%
Annual rate of lease agreement	$ 0.3
Five-Year Option Lease From November 1, 2032 Through October 31, 2037 \| Related Party
Operating Leased Assets [Line Items]
Option to extend lease, years	5 years
Period for extended lease	November 1, 2032 through October 31, 2037
Five-Year Option Lease From November 1, 2037 Through October 31, 2042 \| Related Party
Operating Leased Assets [Line Items]
Option to extend lease, years	5 years
Period for extended lease	November 1, 2037 through October 31, 2042

LEASES AND RELATED PARTY LEASES (Schedule Of Minimum Lease Payments) (Details) $ in Thousands	Dec. 31, 2015 USD ($)
Operating Leased Assets [Line Items]
2016	$ 9,955
2017	7,373
2018	4,723
2019	4,000
2020	2,192
Thereafter	22,460
Total minimum lease payments	50,703
Related Parties
Operating Leased Assets [Line Items]
2016	272
2017	276
2018	296
2019	296
2020	296
Thereafter	3,497
Total minimum lease payments	4,933
Third Parties
Operating Leased Assets [Line Items]
2016	9,683
2017	7,097
2018	4,427
2019	3,704
2020	1,896
Thereafter	18,963
Total minimum lease payments	$ 45,770

LEASES AND RELATED PARTY LEASES (Schedule of Future Minimum Lease Payments for Capital Leases) (Details) $ in Thousands	Dec. 31, 2015 USD ($)
Leases [Abstract]
2016	$ 672
Total minimum lease payments	672
Amount representing interest	18
Present value of minimum lease payments	$ 654

INCOME TAXES (Schedule Of Income Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States operations	$ 37,450	$ 21,349	$ 6,512
Foreign operations	23,221	24,217	12,274
Income from continuing operations before income taxes	$ 60,671	$ 45,566	$ 18,786

INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal statutory rate	35.00%	35.00%	35.00%
Increase (decrease) in income taxes resulting from:
State income taxes, net of federal tax benefit	1.30%	5.60%	0.20%
Foreign operations	(12.50%)	(16.70%)	(27.20%)
Spine valuation allowance	61.10%	0.00%	0.00%
Charitable contributions	(1.00%)	(2.70%)	(0.90%)
Domestic production activities deduction	(2.40%)	(2.70%)	(0.00%)
Intercompany profit in inventory	3.10%	(0.40%)	(1.40%)
Nondeductible facilitative costs	3.10%	1.10%	0.00%
Changes in valuation allowances	0.30%	2.10%	1.50%
Uncertain tax positions	0.20%	(3.40%)	(13.80%)
Research and development credit	(1.90%)	(1.80%)	(5.70%)
Return to provision	1.70%	1.40%	(9.80%)
Other	0.70%	2.80%	4.80%
Effective tax rate	88.70%	20.30%	(17.30%)

INCOME TAXES (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Change in effective income tax rate during the period	68.40%
Income tax benefit for release of tax contingency reserve	$ 0.4	$ 2.1
Effective income tax rate reconciliation, foreign income tax rate differential, increase (decrease), amount	$ 2.3	$ (1.2)
Effective foreign income tax rate	10.60%	4.90%	44.50%
Change in effective foreign income tax rate during period	(5.70%)	(39.60%)	33.00%
Income tax expense for repatriation of foreign earnings			$ 1.0
Undistributed earnings of foreign subsidiaries	$ 261.3
Estimated tax liability on undistributed earnings of foreign subsidiaries	37.9
Operating loss carryforwards, not subject to expiration	18.8
Deferred tax assets, valuation allowance	4.9	$ 6.8	7.3
Deferred tax assets, gross	82.5	91.1	91.9
Valuation allowances and reserves, period increase (decrease)	(1.9)	(0.5)
Unrecognized tax benefits that would impact effective tax rate	1.1
Amount of unrecorded benefit expected to be recognized	0.5
Income tax penalties and interest expense		0.2	0.8
Penalties and interest accrued		$ 0.1	$ 0.4
Internal Revenue Service (IRS)
Income Tax [Line Items]
Operating loss carryforwards	34.4
Foreign Tax Authority
Income Tax [Line Items]
Operating loss carryforwards	21.7
Operating loss carryforwards, subject to expiration	2.9
State and Local Jurisdiction
Income Tax [Line Items]
Operating loss carryforwards	$ 14.2

INCOME TAXES (Schedule Of Provision For Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$ 46,665	$ 10,330	$ (2,931)
State	2,301	2,124	399
Foreign	5,205	3,666	632
Total current	54,171	16,120	(1,900)
Deferred:
Federal	1,282	(5,524)	(2,409)
State	(394)	695	(1,136)
Foreign	(1,239)	(2,020)	2,204
Total deferred	(351)	(6,849)	(1,341)
Provision (benefit) for income taxes	$ 53,820	$ 9,271	$ (3,241)

INCOME TAXES (Schedule Of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Doubtful accounts	$ 0	$ 1,727
Inventory related items	0	30,017
Tax credits	0	3,156
Accrued vacation	0	3,310
Accrued bonus	0	5,596
Other	0	2,694
Total current deferred tax assets	0	46,500
Less valuation allowance	0	(528)
Current deferred tax assets after valuation allowance	0	45,972
Current liabilities:
Other	0	(483)
Total current deferred tax liabilities	0	(483)
Net current deferred tax assets	0	45,489
Non-current assets:
Doubtful accounts	1,943	0
Inventory related items	24,417	0
Tax credits	3,137	0
Accrued vacation	2,713	0
Accrued bonus	7,555	0
Stock compensation	16,222	14,840
Deferred revenue	767	3
Net operating loss carryforwards	17,548	17,899
Federal & state tax credits	6,227	12,278
Other	1,952	(402)
Total non-current deferred tax assets	82,481	44,618
Less valuation allowance	(4,887)	(6,244)
Non-current deferred tax assets after valuation allowance	77,594	38,374
Non-current liabilities:
Intangible & fixed assets	(225,328)	(148,714)
Other	(225)	(665)
Total non-current deferred tax liabilities	(225,553)	(149,379)
Deferred Tax Assets, Net, Noncurrent	(147,959)	(111,005)
Total net deferred tax assets (liabilities)	$ (147,959)	$ (65,516)

INCOME TAXES (Schedule of Uncertain Tax Benefits Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Uncertain Tax Benefits [Roll Forward]
Balance, beginning of year	$ 959	$ 3,040	$ 5,874
Gross increases:
Current year tax positions	0	0	259
Prior years' tax positions	541	527	546
Gross decreases:
Prior years' tax positions	0	(286)	(476)
Settlements	0	(828)	0
Statute of limitations lapses	(404)	(1,494)	(3,163)
Other	(11)	0	0
Balance, end of year	$ 1,085	$ 959	$ 3,040

NET (LOSS) INCOME PER SHARE (Narrative) (Details) - USD ($) $ in Thousands, shares in Millions		6 Months Ended	12 Months Ended
	Jul. 01, 2015	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Allocated share-based compensation expense			$ 15,450	$ 14,554	$ 9,842
Shares excluded from computation as their effect would be antidilutive			0.1	0.2	0.7
Additional EPS shares		0.2	0.2
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff \| SeaSpine Inc.
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share-based compensation arrangement by share-based payment award, plan modification, incremental compensation cost	$ 4,400
Allocated share-based compensation expense		$ 3,300	$ 3,300
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized		$ 1,100	$ 1,100

NET (LOSS) INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Basic net income per share:
Net (loss) income	$ 14,980	$ (31,881)	$ 12,020	$ 11,732	$ 20,405	$ 8,990	$ 4,282	$ 2,618	$ 6,851	$ 36,295	$ 22,027
Loss from discontinued operations, net of tax									(10,370)	(2,291)	(43,094)
Net (loss) income	$ 14,980	$ (31,881)	$ 4,998	$ 8,384	$ 17,166	$ 9,807	$ 4,825	$ 2,206	$ (3,519)	$ 34,004	$ (21,067)
Weighted average common shares outstanding									34,495	32,432	28,416
Basic net income per common share from continuing operations	$ 0.41	$ (0.90)	$ 0.36	$ 0.36	$ 0.63	$ 0.28	$ 0.13	$ 0.08	$ 0.20	$ 1.12	$ 0.78
Basic net loss per common share from discontinued operations									(0.30)	(0.07)	(1.52)
Net (loss) income per share - basic	$ 0.41	$ (0.90)	$ 0.15	$ 0.26	$ 0.53	$ 0.30	$ 0.15	$ 0.07	$ (0.10)	$ 1.05	$ (0.74)
Diluted net income per share:
Net (loss) income	$ 14,980	$ (31,881)	$ 12,020	$ 11,732	$ 20,405	$ 8,990	$ 4,282	$ 2,618	$ 6,851	$ 36,295	$ 22,027
Loss from discontinued operations (net of tax benefit)									(10,370)	(2,291)	(43,094)
Net (loss) income	$ 14,980	$ (31,881)	$ 4,998	$ 8,384	$ 17,166	$ 9,807	$ 4,825	$ 2,206	$ (3,519)	$ 34,004	$ (21,067)
Weighted average common shares outstanding									34,495	32,432	28,416
Effect of dilutive securities:
2016 Convertible notes									461
Stock options and restricted stock (in shares)									721	528	386
Weighted average common shares for diluted earnings per share (in shares)									35,677	32,960	28,802
Diluted net income per common share from continuing operations	$ 0.39	$ (0.90)	$ 0.35	$ 0.35	$ 0.62	$ 0.27	$ 0.13	$ 0.08	$ 0.19	$ 1.10	$ 0.76
Diluted net loss per common share from discontinued operations									(0.29)	(0.07)	(1.50)
Net (loss) income per share - diluted	$ 0.39	$ (0.90)	$ 0.15	$ 0.25	$ 0.52	$ 0.30	$ 0.15	$ 0.07	$ (0.10)	$ 1.03	$ (0.74)

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014	$ (23,488)
Other comprehensive income before reclassifications	(24,940)
Amounts reclassified from accumulated other comprehensive income	526
Current period other comprehensive income (loss)	(24,414)
Balance at December 31, 2015	(47,902)
Gains and Losses on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014	(512)
Other comprehensive income before reclassifications	(14)
Amounts reclassified from accumulated other comprehensive income	526
Current period other comprehensive income (loss)	512
Balance at December 31, 2015	0
Defined Benefit Pension Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014	(906)
Other comprehensive income before reclassifications	915
Amounts reclassified from accumulated other comprehensive income	0
Current period other comprehensive income (loss)	915
Balance at December 31, 2015	9
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014	(22,070)
Other comprehensive income before reclassifications	(25,841)
Amounts reclassified from accumulated other comprehensive income	0
Current period other comprehensive income (loss)	(25,841)
Balance at December 31, 2015	$ (47,911)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Reclassification out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense	$ (23,517)	$ (21,967)	$ (19,725)
Cost of goods sold	326,542	302,946	279,548
Tax benefit	(53,820)	(9,271)	$ 3,241
Gains and Losses on Cash Flow Hedges \| Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Tax benefit	397	751
Net of tax	(526)	(996)
Interest rate swap \| Gains and Losses on Cash Flow Hedges \| Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense	$ (923)	$ (1,747)

COMMITMENTS AND CONTINGENCIES (Details) - TEI Biosciences Inc and TEI Medical Inc. $ in Millions	Jul. 17, 2015 USD ($) case
Loss Contingencies [Line Items]
Loss contingency, pending claims, number \| case	50
Business combination, indemnification assets, amount as of acquisition date	$ 3.0
Indemnification period one - up to fifteen months after close
Loss Contingencies [Line Items]
Business combination, indemnification assets, range of outcomes, value, high	$ 30.0
Business combination, indemnification assets, period of indemnification	15 months
Indemnification period two - up to three years after close
Loss Contingencies [Line Items]
Business combination, indemnification assets, range of outcomes, value, low	$ 20.0
Business combination, indemnification assets, range of outcomes, value, high	$ 30.0
Business combination, indemnification assets, period of indemnification	3 years
Third party insurer
Loss Contingencies [Line Items]
Business combination, indemnification assets, amount as of acquisition date	$ 3.0

SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details) product in Thousands		3 Months Ended	12 Months Ended
	Jul. 31, 2015 Segment	Mar. 31, 2015 Segment	Dec. 31, 2015 Segment product	Dec. 31, 2014 Segment
Segment Reporting [Abstract]
Number of reportable segments \| Segment	3	3	2	5
Specialty Surgical Solutions
Segment Reporting Information [Line Items]
Number of products offered \| product			60

SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue from External Customer [Line Items]
Segment Net Sales	$ 241,160	$ 226,367	$ 212,673	$ 202,534	$ 219,074	$ 197,523	$ 197,043	$ 183,077	$ 882,734	$ 796,717	$ 696,832
Segment Profit									330,323	295,403	217,372
Amortization									(9,953)	(6,810)	(7,099)
Corporate and other									(240,783)	(220,736)	(174,900)
Operating income									79,587	67,857	35,373
Specialty Surgical Solutions
Revenue from External Customer [Line Items]
Segment Net Sales									586,918	554,872	463,296
Segment Profit									242,479	210,146	145,108
Orthopedics and Tissue Technologies
Revenue from External Customer [Line Items]
Segment Net Sales									295,816	241,845	233,536
Segment Profit									$ 87,844	$ 85,257	$ 72,264

SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Total revenues	$ 241,160	$ 226,367	$ 212,673	$ 202,534	$ 219,074	$ 197,523	$ 197,043	$ 183,077	$ 882,734	$ 796,717	$ 696,832
Total long-lived assets	213,147				220,354				213,147	220,354
United States
Segment Reporting Information [Line Items]
Total revenues									680,824	596,303	521,244
Total long-lived assets	192,900				197,897				192,900	197,897
Europe
Segment Reporting Information [Line Items]
Total revenues									103,057	99,207	85,448
Total long-lived assets	19,169				21,218				19,169	21,218
Rest of the World
Segment Reporting Information [Line Items]
Total revenues									98,853	101,207	$ 90,140
Total long-lived assets	$ 1,078				$ 1,239				$ 1,078	$ 1,239

SELECTED QUARTERLY INFORMATION - UNAUDITED (Selected Quarterly Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Selected Quarterly Financial Information [Abstract]
Total revenue, net	$ 241,160	$ 226,367	$ 212,673	$ 202,534	$ 219,074	$ 197,523	$ 197,043	$ 183,077	$ 882,734	$ 796,717	$ 696,832
Gross margin	151,159	140,298	137,422	127,313	134,050	123,627	123,538	112,556	556,192	493,771
Net (loss) income	$ 14,980	$ (31,881)	$ 12,020	$ 11,732	$ 20,405	$ 8,990	$ 4,282	$ 2,618	$ 6,851	$ 36,295	$ 22,027
Income from continuing operations	$ 0.41	$ (0.90)	$ 0.36	$ 0.36	$ 0.63	$ 0.28	$ 0.13	$ 0.08	$ 0.20	$ 1.12	$ 0.78
Income from continuing operations	$ 0.39	$ (0.90)	$ 0.35	$ 0.35	$ 0.62	$ 0.27	$ 0.13	$ 0.08	$ 0.19	$ 1.10	$ 0.76
Net (loss) income	$ 14,980	$ (31,881)	$ 4,998	$ 8,384	$ 17,166	$ 9,807	$ 4,825	$ 2,206	$ (3,519)	$ 34,004	$ (21,067)
Earnings Per Share, Basic (USD per share)	$ 0.41	$ (0.90)	$ 0.15	$ 0.26	$ 0.53	$ 0.30	$ 0.15	$ 0.07	$ (0.10)	$ 1.05	$ (0.74)
Earnings Per Share, Diluted (USD per share)	$ 0.39	$ (0.90)	$ 0.15	$ 0.25	$ 0.52	$ 0.30	$ 0.15	$ 0.07	$ (0.10)	$ 1.03	$ (0.74)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts and sales returns and allowances
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 5,659	$ 5,126	$ 4,837
Charged to Costs and Expenses	1,262	2,211	1,292
Charged to Other Accounts	0	0	0
Deductions	(1,349)	(1,678)	(1,003)
Balance at End of Period	5,572	5,659	5,126
Deferred tax asset valuation allowance
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	6,772	7,283	12,213
Charged to Costs and Expenses	80	3	(5,326)
Charged to Other Accounts	0	0	0
Deductions	(1,965)	(514)	396
Balance at End of Period	$ 4,887	$ 6,772	$ 7,283

TREASURY STOCK	12 Months Ended
TREASURY STOCK	Dec. 31, 2015
Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract]
TREASURY STOCK	TREASURY STOCK On October 28, 2014, the Board of Directors terminated the October 2012 authorization and authorized up to $75.0 million of its outstanding common stock through December 2016. As of December 31, 2015 there remained $75.0 million available for repurchases under this authorization. There were no cash treasury stock repurchases during the years ended December 31, 2015 or December 31, 2014.

RETIREMENT BENEFIT PLANS (Changes In Projected Benefit Obligation And Fair Value Of Plan Assets) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2015 USD ($)
CHANGE IN PLAN ASSETS
Employer contributions	$ 1.8